

=>

Uploading 09980475 (amended).str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 18:38:41 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 467858 TO ITERATE

0.2% PROCESSED 1000 ITERATIONS

4 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
 BATCH **INCOMPLETE**

PROJECTED ITERATIONS: EXCEEDS 1000000

PROJECTED ANSWERS: EXCEEDS 34834

L2 4 SEA SSS SAM L1

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1840

L3 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L4 SCREEN CREATED

=>

Uploading C:\STNEXP4\QUERIES\09980475 (amended).str

L5 STRUCTURE UPLOADED

=> que L5 AND L3 NOT L4

L6 QUE L5 AND L3 NOT L4

=> d l6

L6 HAS NO ANSWERS

L3 SCR 1840

L4 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L5 STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.
 L6 QUE L5 AND L3 NOT L4

=> s 16 sss sam

SAMPLE SEARCH INITIATED 18:41:27 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 318001 TO ITERATE

0.3% PROCESSED 1000 ITERATIONS 2 ANSWERS
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
 BATCH **INCOMPLETE**
 PROJECTED ITERATIONS: EXCEEDS 1000000
 PROJECTED ANSWERS: EXCEEDS 11208

L7 2 SEA SSS SAM L5 AND L3 NOT L4

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1840

L8 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L9 SCREEN CREATED

=>

Uploading C:\STNEXP4\QUERIES\09980475 (amended).str

L10 STRUCTURE UPLOADED

=> que L10 AND L8 NOT L9

L11 QUE L10 AND L8 NOT L9

=> d 111

L11 HAS NO ANSWERS

L8 SCR 1840

L9 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L10 STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.
 L11 QUE L10 AND L8 NOT L9

=> s 111 sss sam

SAMPLE SEARCH INITIATED 18:43:03 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 318001 TO ITERATE

0.3% PROCESSED 1000 ITERATIONS 1 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
 BATCH **INCOMPLETE**
 PROJECTED ITERATIONS: EXCEEDS 1000000
 PROJECTED ANSWERS: EXCEEDS 5291

L12 1 SEA SSS SAM L10 AND L8 NOT L9

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1840

L13 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L14 SCREEN CREATED

=>

Uploading C:\STNEXP4\QUERIES\09980475 (amended).str

L15 STRUCTURE UPLOADED

=> que L15 AND L13 NOT L14

L16 QUE L15 AND L13 NOT L14

=> d l16

L16 HAS NO ANSWERS

L13 SCR 1840

L14 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L15 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

L16 QUE L15 AND L13 NOT L14

=> s l16 sss sam

SAMPLE SEARCH INITIATED 18:51:10 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 203967 TO ITERATE

0.5% PROCESSED 1000 ITERATIONS
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
 BATCH **INCOMPLETE**
 PROJECTED ITERATIONS: EXCEEDS 1000000
 PROJECTED ANSWERS: EXCEEDS 0

L17 0 SEA SSS SAM L15 AND L13 NOT L14

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1840

L18 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L19 SCREEN CREATED

=>

Uploading C:\STNEXP4\QUERIES\09980475 (amended).str

L20 STRUCTURE UPLOADED

=> que L20 AND L18 NOT L19

L21 QUE L20 AND L18 NOT L19

=> d l21

L21 HAS NO ANSWERS

L18 SCR 1840

L19 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L20 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

L21 QUE L20 AND L18 NOT L19

=> s l21 sss sam

SAMPLE SEARCH INITIATED 18:53:40 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 44559 TO ITERATE

2.2% PROCESSED 1000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

3 ANSWERS

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**

PROJECTED ITERATIONS: 878609 TO 903751

PROJECTED ANSWERS: 1980 TO 3366

L22 3 SEA SSS SAM L20 AND L18 NOT L19

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1840

L23 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L24 SCREEN CREATED

=>

Uploading C:\STNEXP4\QUERIES\09980475 (amended - example).str

L25 STRUCTURE UPLOADED

=> que L25 AND L23 NOT L24

L26 QUE L25 AND L23 NOT L24

=> d l26

L26 HAS NO ANSWERS

L23 SCR 1840

L24 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L25 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

L26 QUE L25 AND L23 NOT L24

=> s l26 sss sam

SAMPLE SEARCH INITIATED 19:00:46 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1950 TO ITERATE

51.3% PROCESSED 1000 ITERATIONS

0 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 36352 TO 41648

PROJECTED ANSWERS: 0 TO 0

L27 0 SEA SSS SAM L25 AND L23 NOT L24

=> s l26 sss ful

FULL SEARCH INITIATED 19:00:57 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 39686 TO ITERATE

100.0% PROCESSED 39686 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

L28 0 SEA SSS FUL L25 AND L23 NOT L24

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1840

L29 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L30 SCREEN CREATED

=>

Uploading C:\STNEXP4\QUERIES\09980475 (amended - example).str

L31 STRUCTURE UPLOADED

=> que L31 AND L29 NOT L30

L32 QUE L31 AND L29 NOT L30

=> d l32

L32 HAS NO ANSWERS

L29 SCR 1840

L30 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L31 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

L32 QUE L31 AND L29 NOT L30

=> s l32 sss sam

SAMPLE SEARCH INITIATED 19:01:40 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1961 TO ITERATE

51.0% PROCESSED 1000 ITERATIONS

17 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 36564 TO 41876

PROJECTED ANSWERS: 320 TO 1012

L33 17 SEA SSS SAM L31 AND L29 NOT L30

=> s l32 sss ful

FULL SEARCH INITIATED 19:02:15 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 39854 TO ITERATE

100.0% PROCESSED 39854 ITERATIONS

860 ANSWERS

SEARCH TIME: 00.00.01

L34 860 SEA SSS FUL L31 AND L29 NOT L30

=> s l34

L35 73 L34

=> s immun?

L36 733739 IMMUN?

=> s l35 and l36

L37 5 L35 AND L36

=> d 137 1-5 bib,ab,hitstr

L37 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2003:737995 CAPLUS
 DN 139:257708
 TI Novel fluorescent labeling compound
 IN Matsumoto, Kazuko; Yuan, Jingli; Wang, Guilan; Tan, Mingqian
 PA Japan
 SO PCT Int. Appl., 69 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

not prior

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003076938	A1	20030918	WO 2003-JP2774	20030310
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI JP 2002-63961 A 20020308
 JP 2002-271924 A 20020918
 OS MARPAT 139:257708

AB A novel fluorescent labeling reagent is provided, which is characterized by its structure possessing a binding group with a substance to be labeled (e.g., biol. substance, physiol. active substance), and its property of easily forming a complex with a rare earth metal ion. Furthermore, the complex of the reagent with a rare earth metal ion is sufficiently stable in an aq. soln., and possesses a sufficient fluorescent intensity and a long fluorescence life regardless of the kind of a buffer. Also provided are a complex consisting of the labeling reagent and a rare earth metal ion, a fluorescent labeling agent contg. the complex, a fluorescent labeling method using this complex as a labeling agent, and a fluorescent measuring method and a fluorescent measuring reagent using this fluorescent labeling agent. The fluorescent labeling reagent comprises a compd. having a 2,2':6',2''-tripyridine skeleton or a 2,6-dipyrazolpyridine skeleton, and having a group capable of binding to a substance to be labeled (e.g., biol. substance, physiol. active substance) and a group capable of forming a complex with a rare earth metal ion.


IT 600730-01-6P 600730-02-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(novel fluorescent labeling compd. consisting of rare earth metal ion complex)


RN 600730-01-6 CAPLUS

CN Glycine, N,N'-[[4'-(4'-amino[1,1'-biphenyl]-4-yl)[2,2':6',2''-terpyridine]-6,6''-diyl]bis(methylene)]bis[N-(2-ethoxy-2-oxoethyl)-, diethyl ester (9CI) (CA INDEX NAME)



RN 600730-02-7 CAPLUS

CN Glycine, N,N'-[[4'-(4'-amino[1,1'-biphenyl]-4-yl)[2,2':6',2''-terpyridine]-6,6''-diyl]bis(methylene)]bis[N-(carboxymethyl)- (9CI) (CA INDEX NAME)



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L37 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:555467 CAPLUS
 DN 137:109290
 TI Preparation of hetero-tricyclic compounds having substituted amino groups
 as inhibitors of production of IgE antibody
 IN Tsuru, Tatsuo; Takechi, Shozo; Horibe, Isao
 PA Shionogi & Co., Ltd., Japan
 SO PCT Int. Appl., 166 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

not prior

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002057237	A1	20020725	WO 2002-JP260	20020117
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP	1354877	A1	20031022	EP 2002-716308	20020117
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI	JP 2001-12888	A	20010122		
	WO 2002-JP260	W	20020117		
OS	MARPAT 137:109290				

AB The title compds. including 2-amino-5-(1,1'-biphenyl-4-yl)pyridine, 2-amino-5-(1,1'-biphenyl-4-yl)pyrimidine, and 1,4-(2-amino-5-pyridyl)benzene, 4,7-(2-amino-5-pyridyl)benzimidazole, and 5,8-(2-amino-5-pyridyl)benzopyrazine derivs. represented by the general formula [I; wherein X = N or CR₄; Y = N or CR₁₃; Z = N or CR₁₅; R_{1a}, R_{1b}, R_{1c}, R_{1d} = independently H, (un)substituted lower alkyl, lower alkenyl, lower alkynyl, optionally halo-substituted lower alkylsulfonyl, lower alkoxy carbonyl, cycloalkyl, arylsulfonyl, optionally alkyl-substituted carbamoyl, optionally lower alkyl-substituted sulfamoyl; R₄-R₁₅ = H, halo, HO, CO₂H, guanidino, NO₂, cyano, each (un)substituted lower alkyl, lower alkoxy, lower alkenyl, lower alkenyloxy, cycloalkyloxy, acyl, acyloxy, acyl, lower alkoxy carbonyl, lower alkenyloxycarbonyl, lower alkylthio, lower alkenylthio, NH₂, carbamoyl, or sulfamoyl, etc.] or prodrugs thereof or pharmaceutically acceptable salts or hydrates thereof are prepd. IgE prodn. inhibitors, antiallergic agents, and **immunosuppressants** contg. I are claimed. These compds. exhibit potent IgE-prodn. inhibitory activity and excellent **immunosuppressive** and/or antiallergic effects. Thus, Suzuki coupling of 1,4-diiodo-2,3,5,6-tetramethylbenzene with 2-isopropylamino-5-pyridylboronic acid (prepn. given) in the presence of tetrakis(triphenylphosphine)palladium and K₂CO₃ in a mixt. of 1,2-dimethoxyethane, ethanol, and water under refluxing overnight gave 82% 1,4-bis(2-isopropylamino-5-pyridyl)-2,3,5,6-tetramethylbenzene (II). When administered to rats at 40 mg/kg p.o. daily for 10 days, many of the compds. I, e.g. 1-(4-aminophenyl)-4-(2-isopropylamino-5-pyridyl)-2,3,5,6-tetramethylbenzene and 2-amino-5-(1,1'-biphenyl-4-yl)pyrimidine (III), almost completely inhibited the prodn. of anti-ovalbumin antibody. A tablet formulation contg. II was prepd.

IT 234427-31-7P 234427-76-0P 234427-78-2P

443334-60-9P 443334-61-0P 443334-62-1P
443334-63-2P 443334-64-3P 443334-65-4P
443334-66-5P 443334-67-6P 443334-68-7P
443334-69-8P 443334-70-1P 443334-71-2P
443334-72-3P 443334-73-4P 443334-74-5P
443334-75-6P 443334-76-7P 443334-77-8P
443334-78-9P 443334-79-0P 443334-80-3P
443334-81-4P 443334-82-5P 443334-83-6P
443334-84-7P 443334-85-8P 443334-86-9P
443334-87-0P 443334-88-1P 443334-89-2P
443334-90-5P 443334-91-6P 443334-92-7P
443334-93-8P 443334-94-9P 443334-95-0P
443334-96-1P 443334-97-2P 443334-98-3P
443334-99-4P 443335-00-0P 443335-01-1P
443335-02-2P 443335-03-3P 443335-04-4P
443335-05-5P 443335-06-6P 443335-07-7P
443335-08-8P 443335-09-9P 443335-10-2P
443335-11-3P 443335-12-4P 443335-13-5P
443335-14-6P 443335-15-7P 443335-16-8P
443335-17-9P 443335-18-0P 443335-19-1P
443335-20-4P 443335-21-5P 443335-22-6P
443335-23-7P 443335-24-8P 443335-25-9P
443335-26-0P 443335-27-1P 443335-28-2P
443335-29-3P 443335-30-6P 443335-31-7P
443335-32-8P 443335-33-9P 443335-34-0P
443335-35-1P 443335-36-2P 443335-37-3P
443335-38-4P 443335-39-5P 443335-40-8P
443335-41-9P 443335-42-0P 443335-43-1P
443335-44-2P 443335-45-3P 443335-46-4P
443335-47-5P 443335-48-6P 443335-49-7P
443335-50-0P 443335-51-1P 443335-52-2P
443335-53-3P 443335-54-4P 443335-55-5P
443335-56-6P 443335-57-7P 443335-58-8P
443335-59-9P 443335-60-2P 443335-61-3P
443335-62-4P 443335-63-5P 443335-64-6P
443335-65-7P 443335-66-8P 443335-67-9P
443335-68-0P 443335-69-1P 443335-70-4P
443335-71-5P 443335-72-6P 443335-73-7P
443335-74-8P 443335-75-9P 443335-76-0P
443335-77-1P 443335-78-2P 443335-79-3P
443335-80-6P 443335-81-7P 443335-82-8P
443335-83-9P 443335-84-0P 443337-23-3P
443337-24-4P 443337-25-5P 443337-26-6P
443337-27-7P 443337-28-8P 443337-29-9P
443337-30-2P 443337-31-3P 443337-32-4P
443337-33-5P 443337-34-6P 443337-38-0P
443337-40-4P 443337-41-5P 443337-42-6P
443337-43-7P 443337-44-8P 443337-45-9P
443337-46-0P 443337-47-1P 443337-48-2P
443337-49-3P 443337-50-6P 443337-51-7P
443337-52-8P 443337-53-9P 443337-54-0P
443337-55-1P 443337-56-2P 443337-57-3P
443337-58-4P 443337-59-5P 443337-60-8P
443337-61-9P 443337-62-0P 443337-63-1P
443337-64-2P 443337-65-3P 443337-66-4P
443337-67-5P 443337-68-6P 443337-69-7P
443337-70-0P 443337-71-1P 443337-72-2P
443337-73-3P 443337-74-4P 443337-75-5P


443337-76-6P 443337-77-7P 443337-78-8P
 443337-79-9P 443337-80-2P 443337-81-3P
 443337-82-4P 443337-83-5P 443337-84-6P
 443337-85-7P 443337-86-8P 443337-87-9P
 443337-88-0P 443337-89-1P 443337-90-4P
 443337-91-5P 443337-92-6P 443337-93-7P
 443337-94-8P 443337-95-9P 443337-96-0P
 443337-97-1P 443337-98-2P 443337-99-3P
 443338-01-0P 443338-02-1P 443338-03-2P
 443338-04-3P 443338-05-4P 443338-06-5P
 443338-07-6P 443338-08-7P 443338-09-8P
 443338-10-1P 443338-11-2P 443338-12-3P
 443338-13-4P 443338-14-5P 443338-15-6P
 443338-16-7P 443338-17-8P 443338-18-9P
 443338-19-0P 443338-20-3P 443338-21-4P
 443338-22-5P 443338-23-6P 443338-24-7P
 443338-25-8P 443338-26-9P 443338-27-0P
 443338-28-1P 443338-29-2P 443338-30-5P
 443338-31-6P 443338-32-7P 443338-33-8P
 443338-34-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of hetero-tricyclic compds. having substituted amino groups as inhibitors of prodn. of IgE antibody, antiallergic agents, and immunosuppressants)


RN 234427-31-7 CAPLUS

CN 2-Pyridinamine, N-(3-methyl-2-butenyl)-5-[2,3,5,6-tetramethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 234427-76-0 CAPLUS

CN 2-Pyridinamine, 5-[2,5-dimethoxy-3,6-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 234427-78-2 CAPLUS

CN 2-Pyridinamine, 5-[3'-fluoro-2,5-dimethoxy-3,6-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 443334-60-9 CAPLUS

CN 2-Pyridinamine, 5-(4'-amino-2'-fluoro-2,5-dimethyl[1,1'-biphenyl]-4-yl)-N-propyl- (9CI) (CA INDEX NAME)




RN 443334-61-0 CAPLUS

CN 2-Pyridinamine, 5-[2'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-N-propyl- (9CI) (CA INDEX NAME)




RN 443334-62-1 CAPLUS

CN 2-Pyridinamine, 5-[2'-fluoro-2,5-dimethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]-N-propyl- (9CI) (CA INDEX NAME)




RN 443334-63-2 CAPLUS

CN 2-Pyridinamine, 5-[4'-(cyclopentylamino)-2'-fluoro-2,5-dimethyl[1,1'-biphenyl]-4-yl]-N-propyl- (9CI) (CA INDEX NAME)




RN 443334-64-3 CAPLUS

CN 2-Pyridinamine, 5-[2'-fluoro-2,5-dimethyl-4'-(propylamino)[1,1'-biphenyl]-4-yl]-N-propyl- (9CI) (CA INDEX NAME)




RN 443334-65-4 CAPLUS

CN [1,1'-Biphenyl]-2-ol, 4'-amino-3,5,6-trimethyl-4-[6-(propylamino)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 443334-66-5 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 6-methoxy-5-methyl-4'-[(1-methylethyl)amino]-4-[6-(propylamino)-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443334-67-6 CAPLUS

CN [1,1'-Biphenyl]-2-ol, 6-methoxy-3,5-dimethyl-4'-[(1-methylethyl)amino]-4-[6-(propylamino)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 443334-68-7 CAPLUS

CN Methanesulfonamide, N-[3',6'-dimethoxy-2',5'-dimethyl-4'-[6-[(1-methylethyl)amino]-3-pyridinyl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443334-69-8 CAPLUS

CN Ethanesulfonamide, N-[3',6'-dimethoxy-2',5'-dimethyl-4'-[6-[(1-methylethyl)amino]-3-pyridinyl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443334-70-1 CAPLUS

CN 2-Propanesulfonamide, N-[3',6'-dimethoxy-2',5'-dimethyl-4'-[6-[(1-methylethyl)amino]-3-pyridinyl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443334-71-2 CAPLUS

CN 2-Pyridinamine, 5-[2,5-dimethoxy-3,6-dimethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443334-72-3 CAPLUS

CN 2-Pyridinamine, 5-(4'-amino-2,3,5,6-tetramethyl[1,1'-biphenyl]-4-yl)-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443334-73-4 CAPLUS

CN 2-Pyridinamine, N-(1-methylethyl)-5-[2,3,6-trimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443334-74-5 CAPLUS

CN 2-Pyridinamine, N-(1-methylethyl)-5-[2,3,5,6-tetramethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 443334-75-6 CAPLUS


CN 2-Pyridinamine, 5-[4'-(cyclopentylamino)-2,3,5,6-tetramethyl[1,1'-biphenyl]-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 443334-76-7 CAPLUS


CN 2-Pyridinamine, 5-(4'-amino-2,3'-dimethoxy-3,5,6-trimethyl[1,1'-biphenyl])-N-(1-methylethyl)-

4-yl)-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443334-77-8 CAPLUS

CN 2-Pyridinamine, 5-[3-methoxy-2,5,6-trimethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443334-78-9 CAPLUS

CN [1,1'-Biphenyl]-3-ol, 2,5,6-trimethyl-4'-[(1-methylethyl)amino]-4-[6-[(1-methylethyl)amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 443334-79-0 CAPLUS

CN 2-Pyridinamine, 5-[4'-[(cyclopropylmethyl)amino]-2,3,6-trimethyl[1,1'-biphenyl]-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443334-80-3 CAPLUS

CN 2-Pyridinamine, 5-[4'-(cyclopentylamino)-2,3,6-trimethyl[1,1'-biphenyl]-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)





RN 443334-81-4 CAPLUS

CN 2-Pyridinamine, N-(1-methylethyl)-5-[2,3',5-trimethoxy-3,6-dimethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443334-82-5 CAPLUS

CN 2-Pyridinamine, 5-[4'-[(cyclopropylmethyl)amino]-2,3',5-trimethoxy-3,6-dimethyl[1,1'-biphenyl]-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443334-83-6 CAPLUS

CN 2-Pyridinamine, 5-[4'-[(1-ethylpropyl)amino]-2,5-dimethoxy-3,6-dimethyl[1,1'-biphenyl]-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443334-84-7 CAPLUS

CN [1,1'-Biphenyl]-3-ol, 4'-amino-3'-methoxy-2,5,6-trimethyl-4-[6-[(1-methylethyl)amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 443334-85-8 CAPLUS

CN [1,1'-Biphenyl]-3-ol, 4'-amino-3'-fluoro-2,5,6-trimethyl-4-[6-[(1-methylethyl)amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 443334-86-9 CAPLUS

CN [1,1'-Biphenyl]-3-ol, 3'-fluoro-2,5,6-trimethyl-4'-[(1-methylethyl)amino]-4-[6-[(1-methylethyl)amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 443334-87-0 CAPLUS

CN [1,1'-Biphenyl]-3-ol, 4'-[(cyclopropylmethyl)amino]-3'-fluoro-2,5,6-trimethyl-4-[6-[(1-methylethyl)amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 443334-88-1 CAPLUS

CN 2-Pyridinamine, 6-methyl-N-(1-methylethyl)-5-[2,3,6-trimethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443334-89-2 CAPLUS

CN 2-Pyridinamine, 5-[4'-(cyclopentylamino)-2,3,6-trimethyl[1,1'-biphenyl]-4-yl]-6-methyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443334-90-5 CAPLUS

CN 2-Pyridinamine, 5-(4'-amino-2'-fluoro-2,5-dimethyl[1,1'-biphenyl]-4-yl)-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443334-91-6 CAPLUS

CN 2-Pyridinamine, 5-[2'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443334-92-7 CAPLUS

CN 2-Pyridinamine, 5-[2'-fluoro-2,5-dimethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443334-93-8 CAPLUS

CN 2-Pyridinamine, 5-[2'-fluoro-2,5-dimethyl-4'-(propylamino)[1,1'-biphenyl]-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443334-94-9 CAPLUS

CN 2-Pyridinamine, 4-methyl-N-(1-methylethyl)-5-[2,3,6-trimethyl-4'-[(1-methylethylamino)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 443334-95-0 CAPLUS


CN 2-Pyridinamine, 5-[4'-[(cyclopropylmethyl)amino]-2,3,6-trimethyl[1,1'-biphenyl]-4-yl]-4-methyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 443334-96-1 CAPLUS


CN 2-Pyridinamine, 5-[4'-[(cyclopentylamino)-2,3,6-trimethyl[1,1'-biphenyl]-4-yl]-4-methyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)

yl]-4-methyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443334-97-2 CAPLUS

CN 2-Pyridinamine, 4-methyl-N-(1-methylethyl)-5-[2,3,6-trimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443334-98-3 CAPLUS

CN 2-Pyridinamine, 5-[4'-(2-butyrylamino)-2,3,6-trimethyl[1,1'-biphenyl]-4-yl]-4-methyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443334-99-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-amino-5-methoxy-6-methyl-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443335-00-0 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 5-methoxy-6-methyl-4'--[(1-methylethyl)amino]-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443335-01-1 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 5-methoxy-6-methyl-4'--[(1-methylethyl)amino]-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-4'-(propylamino)-, methyl ester (9CI) (CA INDEX NAME)




RN 443335-02-2 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 5-methoxy-6-methyl-4'--[(3-methyl-2-butenyl)amino]-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443335-03-3 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 5-methoxy-6-methyl-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-4'--[(2-methylpropyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 443335-04-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(cyclopropylamino)-5-methoxy-6-methyl-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443335-05-5 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 6-methoxy-5-methyl-4'-[(1-methylethyl)amino]-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443335-06-6 CAPLUS

CN 2-Pyridinamine, N-(1-methylethyl)-5-[2,3,5,6-tetrafluoro-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443335-07-7 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 4'-amino-6-methoxy-5-methyl-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443335-08-8 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 6-methoxy-5-methyl-4'-[(3-methyl-2-butenyl)amino]-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443335-09-9 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 4'-(cyclopentylamino)-6-methoxy-5-methyl-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443335-10-2 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 4'-[(cyclopropylmethyl)amino]-6-methoxy-5-methyl-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443335-11-3 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 6-methoxy-5-methyl-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-4'-[(2-methylpropyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 443335-12-4 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 6-methoxy-5-methyl-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-4'-(propylamino)-, methyl ester (9CI) (CA INDEX NAME)




RN 443335-13-5 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-amino-2'-fluoro-5-methoxy-6-methyl-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443335-14-6 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 2'-fluoro-5-methoxy-6-methyl-4'-[(1-methylethyl)amino]-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443335-15-7 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 2'-fluoro-5-methoxy-6-methyl-4'--[(3-methyl-2-butenyl)amino]-4-[6-(propylamino)-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)





RN 443335-16-8 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 2'-fluoro-5-methoxy-6-methyl-4'--[(1-methylethyl)amino]-3-pyridinyl]-4'--[(2-methylpropyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 443335-17-9 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-(cyclopentylamino)-2'-fluoro-5-methoxy-6-methyl-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443335-18-0 CAPLUS

CN 2-Pyridinamine, 5-(4'-amino-2,3,5,6-tetrafluoro[1,1'-biphenyl]-4-yl)-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443335-19-1 CAPLUS

CN 2-Pyridinamine, N-(1-methylethyl)-5-[2,3,5,6-tetramethyl-4'-(propylamino)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)





RN 443335-20-4 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 6-methoxy-5-methyl-4'-[(1-methylethyl)amino]-4-[6-[(2-methylpropyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443335-21-5 CAPLUS

CN 2-Pyridinamine, 5-(4'-amino-2,5-dimethoxy-3,6-dimethyl[1,1'-biphenyl]-4-yl)-N-(cyclopropylmethyl)- (9CI) (CA INDEX NAME)





RN 443335-22-6 CAPLUS

CN 2-Pyridinamine, N-(cyclopropylmethyl)-5-[2,5-dimethoxy-3,6-dimethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443335-23-7 CAPLUS

CN 2-Pyridinamine, 5-[4'-(cyclopentylamino)-2,5-dimethoxy-3,6-dimethyl[1,1'-biphenyl]-4-yl]-N-(cyclopropylmethyl)- (9CI) (CA INDEX NAME)




RN 443335-24-8 CAPLUS

CN 2-Pyridinamine, N-(cyclopropylmethyl)-5-[4'-[(cyclopropylmethyl)amino]-2,5-dimethoxy-3,6-dimethyl[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443335-25-9 CAPLUS

CN 2-Pyridinamine, 5-(4'-amino-2,3',5-trimethoxy-3,6-dimethyl[1,1'-biphenyl]-4-yl)-N-(cyclopropylmethyl)- (9CI) (CA INDEX NAME)




RN 443335-26-0 CAPLUS

CN 2-Pyridinamine, N-(cyclopropylmethyl)-5-[2,3,6-trimethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443335-27-1 CAPLUS

CN 2-Pyridinamine, N-(cyclopropylmethyl)-5-[4'-[(cyclopropylmethyl)amino]-2,3,6-trimethyl[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443335-28-2 CAPLUS

CN 2-Pyridinamine, 5-[4'-(cyclopentylamino)-2,3,6-trimethyl[1,1'-biphenyl]-4-yl]-N-(cyclopropylmethyl)- (9CI) (CA INDEX NAME)




RN 443335-29-3 CAPLUS

CN Acetamide, N-(cyclopropylmethyl)-2-methoxy-N-[5-[3,3',6-trimethoxy-4'-[(methoxyacetyl)amino]-2,5-dimethyl[1,1'-biphenyl]-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 443335-30-6 CAPLUS

CN 2-Pyridinamine, N-(cyclopropylmethyl)-5-[2,3',5-trimethoxy-3,6-dimethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)





RN 443335-31-7 CAPLUS

CN 2-Pyridinamine, N-(cyclopropylmethyl)-5-[4'-[(cyclopropylmethyl)amino]-2,3',5-trimethoxy-3,6-dimethyl[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 443335-32-8 CAPLUS


CN 2-Pyridinamine, 5-[4'-(cyclopentylamino)-2,3',5-trimethoxy-3,6-dimethyl[1,1'-biphenyl]-4-yl]-N-(cyclopropylmethyl)- (9CI) (CA INDEX NAME)



RN 443335-33-9 CAPLUS


CN Acetamide, N-[4'-[6-[(cyclopropylmethyl)amino]-3-pyridinyl]-2',3,5'-

trimethoxy-3',6'-dimethyl[1,1'-biphenyl]-4-yl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 443335-34-0 CAPLUS

CN 2-Pyridinamine, N-(cyclopropylmethyl)-5-[2,3,6-trimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443335-35-1 CAPLUS

CN 2-Pyridinamine, 5-[4'-(2-butenylamino)-2,3,6-trimethyl[1,1'-biphenyl]-4-yl]-N-(cyclopropylmethyl)- (9CI) (CA INDEX NAME)




RN 443335-36-2 CAPLUS

CN 2-Pyridinamine, 5-[4'-(2-butynylamino)-2,3',5-trimethoxy-3,6-dimethyl[1,1'-biphenyl]-4-yl]-N-(cyclopropylmethyl)- (9CI) (CA INDEX NAME)




RN 443335-37-3 CAPLUS

CN 2-Pyridinamine, N-(cyclopropylmethyl)-5-[2,3',5-trimethoxy-3,6-dimethyl-4'-(2-pentynylamino)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443335-38-4 CAPLUS

CN Propanamide, N-(cyclopropylmethyl)-2-methyl-N-[5-[3,3',6-trimethoxy-2,5-dimethyl-4'-[(2-methyl-1-oxopropyl)amino][1,1'-biphenyl]-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 443335-39-5 CAPLUS

CN 2-Pyridinamine, N-(cyclopropylmethyl)-6-methyl-5-[2,3,6-trimethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443335-40-8 CAPLUS

CN 2-Pyridinamine, N-(cyclopropylmethyl)-5-[4'-[(cyclopropylmethyl)amino]-2,3,6-trimethyl[1,1'-biphenyl]-4-yl]-6-methyl- (9CI) (CA INDEX NAME)




RN 443335-41-9 CAPLUS

CN 2-Pyridinamine, 5-[4'-(cyclopropylmethyl)-2,3,6-trimethyl[1,1'-biphenyl]-4-yl]-N-(cyclopropylmethyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 443335-42-0 CAPLUS

CN 2-Pyridinamine, N-(cyclopropylmethyl)-6-methyl-5-[2,3,6-trimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)





RN 443335-43-1 CAPLUS

CN 2-Pyridinamine, 5-[4'-(2-butyrylamino)-2,3,6-trimethyl[1,1'-biphenyl]-4-yl]-N-(cyclopropylmethyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 443335-44-2 CAPLUS

CN Acetamide, N-(cyclopropylmethyl)-N-[5-[2,5-dimethoxy-4'-
[(methoxyacetyl)amino]-3,6-dimethyl[1,1'-biphenyl]-4-yl]-2-pyridinyl]-2-
methoxy- (9CI) (CA INDEX NAME)




RN 443335-45-3 CAPLUS

CN Acetamide, N-[4'-[6-[(cyclopropylmethyl)amino]-3-pyridinyl]-3',6'-
dimethoxy-2',5'-dimethyl[1,1'-biphenyl]-4-yl]-2-methoxy- (9CI) (CA INDEX
NAME)




RN 443335-46-4 CAPLUS

CN [1,1'-Biphenyl]-2-ol, 4'-amino-4-[6-[(cyclopropylmethyl)amino]-3-
pyridinyl]-3,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 443335-47-5 CAPLUS

CN [1,1'-Biphenyl]-2-ol, 4-[6-[(cyclopropylmethyl)amino]-3-pyridinyl]-3,5,6-trimethyl-4'-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)




RN 443335-48-6 CAPLUS

CN [1,1'-Biphenyl]-2-ol, 4'-amino-4-[6-[(cyclopropylmethyl)amino]-3-pyridinyl]-3'-fluoro-3,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 443335-49-7 CAPLUS

CN 2-Pyridinamine, N-(cyclopropylmethyl)-5-[2,3,5,6-tetrafluoro-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443335-50-0 CAPLUS


CN [1,1'-Biphenyl]-2-ol, 4-[6-[(cyclopropylmethyl)amino]-3-pyridinyl]-3'-fluoro-3,5,6-trimethyl-4'-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)




RN 443335-51-1 CAPLUS
 CN [1,1'-Biphenyl]-2-ol, 4'-[(cyclopropylmethyl)amino]-4-[6-[(cyclopropylmethyl)amino]-3-pyridinyl]-3'-fluoro-3,5,6-trimethyl- (9CI)
 (CA INDEX NAME)




RN 443335-52-2 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 4-[6-[(cyclopropylmethyl)amino]-3-pyridinyl]-6-methoxy-5-methyl-4'-[(1-methylethyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 443335-53-3 CAPLUS
 CN 2-Pyridinamine, N-(cyclopentylmethyl)-5-[2'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443335-54-4 CAPLUS
 CN 2-Pyridinamine, 5-[2'-chloro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-N-(cyclopentylmethyl)- (9CI) (CA INDEX NAME)




RN 443335-55-5 CAPLUS

CN 2-Pyridinamine, N-(cyclopentylmethyl)-5-[2,2',5-trimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443335-56-6 CAPLUS

CN 2-Pyridinamine, N-(cyclopentylmethyl)-5-[2,2',5-trimethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 443335-57-7 CAPLUS


CN 2-Pyridinamine, 5-(4'-amino-2,3,5,6-tetramethyl[1,1'-biphenyl]-4-yl)-N-(cyclopentylmethyl)- (9CI) (CA INDEX NAME)



RN 443335-58-8 CAPLUS


CN 2-Pyridinamine, N-(cyclopentylmethyl)-5-[2,3,5,6-tetramethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)

2-butenyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443335-59-9 CAPLUS

CN 2-Pyridinamine, N-(cyclopentylmethyl)-5-[2,3,5,6-tetramethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443335-60-2 CAPLUS

CN 2-Pyridinamine, 5-[4'-(cyclopentylamino)-2,3,5,6-tetramethyl[1,1'-biphenyl]-4-yl]-N-(cyclopentylmethyl)- (9CI) (CA INDEX NAME)




RN 443335-61-3 CAPLUS

CN 2-Pyridinamine, N-(cyclopentylmethyl)-5-[2,3,6-trimethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443335-62-4 CAPLUS

CN 2-Pyridinamine, N-(cyclopentylmethyl)-5-[4'-[(cyclopropylmethyl)amino]-2,3,6-trimethyl[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443335-63-5 CAPLUS

CN 2-Pyridinamine, 5-[4'-(cyclopentylamino)-2,3,6-trimethyl[1,1'-biphenyl]-4-yl]-N-(cyclopentylmethyl)- (9CI) (CA INDEX NAME)




RN 443335-64-6 CAPLUS

CN 2-Pyridinamine, N-(cyclopentylmethyl)-5-[2,3,6-trimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443335-65-7 CAPLUS

CN 2-Pyridinamine, N-(cyclopentylmethyl)-6-methyl-5-[2,3,6-trimethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443335-66-8 CAPLUS

CN 2-Pyridinamine, N-(cyclopentylmethyl)-5-[2,3,5,6-tetrafluoro-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443335-67-9 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 4-[6-[(cyclopentylmethyl)amino]-3-pyridinyl]-6-methoxy-5-methyl-4'-[(1-methylethyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 443335-68-0 CAPLUS

CN 2-Pyridinamine, 5-[2'-chloro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 443335-69-1 CAPLUS

CN 2-Pyridinamine, 5-[3'-fluoro-2-methoxy-3,5,6-trimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 443335-70-4 CAPLUS

CN 2-Pyridinamine, 5-[2-methoxy-3,5,6-trimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 443335-71-5 CAPLUS

CN 2-Pyridinamine, 5-[2'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 443335-72-6 CAPLUS

CN 2-Pyridinamine, N-(3-methyl-2-butenyl)-5-[2,2',5-trimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443335-73-7 CAPLUS

CN 2-Pyridinamine, N-(3-methyl-2-butenyl)-5-[2,3,5,6-tetramethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443335-74-8 CAPLUS

CN 2-Pyridinamine, 5-[4'-(cyclopentylamino)-2,3,5,6-tetramethyl[1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 443335-75-9 CAPLUS

CN 2-Pyridinamine, 5-[3'-fluoro-2,5-dimethoxy-3,6-dimethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)





RN 443335-76-0 CAPLUS

CN 2-Pyridinamine, 5-[3'-fluoro-2,5-dimethoxy-3,6-dimethyl-4'-[(2-methylpropyl)amino][1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 443335-77-1 CAPLUS

CN 2-Pyridinamine, 5-[4'-[(cyclopropylmethyl)amino]-3'-fluoro-2,5-dimethoxy-3,6-dimethyl[1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 443335-78-2 CAPLUS

CN 2-Pyridinamine, 5-[3'-fluoro-2,5-dimethoxy-4'-[(2-methoxyethyl)amino]-3,6-dimethyl[1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)





RN 443335-79-3 CAPLUS

CN 2-Pyridinamine, 5-[2,5-dimethoxy-3,6-dimethyl-4'-[(1-methylethyl)amino]-[1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 443335-80-6 CAPLUS

CN 2-Pyridinamine, 5-[4'-[(cyclopropylmethyl)amino]-2,5-dimethoxy-3,6-dimethyl[1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 443335-81-7 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 6-methoxy-5-methyl-4-[6-[(3-methyl-2-butenyl)amino]-3-pyridinyl]-4'-[(1-methylethyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 443335-82-8 CAPLUS

CN 2-Pyridinamine, N-(3-methyl-2-butenyl)-5-[2,3,5,6-tetrafluoro-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443335-83-9 CAPLUS

CN 2-Pyridinamine, 5-[2'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 443335-84-0 CAPLUS

CN Ethanesulfonamide, N-[5-[2'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 443337-23-3 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 2'-fluoro-6-methoxy-5-methyl-4'-[(1-methylethyl)amino]-4-[6-[(2-methylpropyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443337-24-4 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 2'-fluoro-6-methoxy-5-methyl-4'--[(1-methylethyl)amino]-4-[6-(propylamino)-3-pyridinyl]-, methyl ester (9CI)
(CA INDEX NAME)




RN 443337-25-5 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 4-[6-[(cyclopropylmethyl)amino]-3-pyridinyl]-2'-fluoro-6-methoxy-5-methyl-4'--[(1-methylethyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 443337-26-6 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 4-[6-(cyclopentylamino)-3-pyridinyl]-2'-fluoro-6-methoxy-5-methyl-4'--[(1-methylethyl)amino]-, methyl ester (9CI)
(CA INDEX NAME)




RN 443337-27-7 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 2'-fluoro-6-methoxy-5-methyl-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-4'--[(phenylmethyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 443337-28-8 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 2'-fluoro-6-methoxy-5-methyl-4'-[(1-methylethyl)amino]-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443337-29-9 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 2'-fluoro-6-methoxy-5-methyl-4'-[(2-methylpropyl)amino]-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)





RN 443337-30-2 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 2'-fluoro-6-methoxy-5-methyl-4'-[(1-methylethyl)amino]-3-pyridinyl]-4'-(propylamino)-, methyl ester (9CI) (CA INDEX NAME)




RN 443337-31-3 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 4'-[(cyclopropylmethyl)amino]-2'-fluoro-6-methoxy-5-methyl-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443337-32-4 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 2'-fluoro-6-methoxy-5-methyl-4'-[(3-methyl-2-butenyl)amino]-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443337-33-5 CAPLUS

CN 2-Pyridinamine, N-(1-methylethyl)-5-[2,3,5,6-tetramethyl-4'-[(2-methylpropyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443337-34-6 CAPLUS

CN 2-Pyridinamine, 5-[4'-[(cyclopropylmethyl)amino]-2,3,5,6-tetrafluoro[1,1'-biphenyl]-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443337-38-0 CAPLUS

CN Propanamide, N-[3'-fluoro-2',5',6'-trimethyl-4'-[6-[(1-methylethyl)amino]-3-pyridinyl][1,1'-biphenyl]-4-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 443337-40-4 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 2,5,6-trimethyl-4'-[(3-methyl-2-butenyl)amino]-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443337-41-5 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 2,5,6-trimethyl-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-4'-[(2-methylpropyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 443337-42-6 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 2,5,6-trimethyl-4'-[(1-methylethyl)amino]-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 443337-43-7 CAPLUS


CN [1,1'-Biphenyl]-3-carboxylic acid, 2,5,6-trimethyl-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-4'-(propylamino)-, methyl ester (9CI) (CA INDEX NAME)



RN 443337-44-8 CAPLUS


CN [1,1'-Biphenyl]-3-carboxylic acid, 4'-[(cyclopropylmethyl)amino]-2,5,6-trimethyl-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-, methyl ester (9CI)

(CA INDEX NAME)




RN 443337-45-9 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 2,5-dimethyl-4'-[(1-methylethyl)amino]-6-[(2-methylpropyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 443337-46-0 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 2,5-dimethyl-4'-[(1-methylethyl)amino]-4'-[(2-methylpropyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 443337-47-1 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 4'-[(cyclopropylmethyl)amino]-2,5-dimethyl-4'-[(1-methylethyl)amino]-6-[(1-methylethyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443337-48-2 CAPLUS

CN Benzenesulfonamide, N-[2',3',5',6'-tetramethyl-4'-[6-[(1-methylethyl)amino]-3-pyridinyl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443337-49-3 CAPLUS

CN Benzamide, N-[2',3',5',6'-tetramethyl-4'-[6-[(1-methylethyl)amino]-3-pyridinyl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443337-50-6 CAPLUS

CN 2-Pyridinamine, N-cyclopentyl-5-[2,3,6-trimethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 443337-51-7 CAPLUS
 CN 2-Pyridinamine, N-cyclopentyl-5-[4'-[(cyclopropylmethyl)amino]-2,3,6-trimethyl[1,1'-biphenyl]-4-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 443337-52-8 CAPLUS
 CN [1,1'-Biphenyl]-2-ol, 4'-[(cyclopropylmethyl)amino]-4-[6-[(cyclopropylmethyl)amino]-3-pyridinyl]-3'-fluoro-3,5,6-trimethyl-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 443337-53-9 CAPLUS
 CN [1,1'-Biphenyl]-3-carboxylic acid, 6-methoxy-5-methyl-4'-[(1-methylethyl)amino]-4-[6-[(methylsulfonyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443337-54-0 CAPLUS

CN 2-Pyridinamine, 5-[4'-(cyclopentylamino)-2,3,5,6-tetrafluoro[1,1'-biphenyl]-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443337-55-1 CAPLUS

CN 2-Pyridinamine, N-(1-methylethyl)-5-[2,3,5,6-tetrafluoro-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443337-56-2 CAPLUS

CN Cyclopropanecarboxamide, N-[2',3',5',6'-tetramethyl-4'-[6-[(1-methylethyl)amino]-3-pyridinyl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443337-57-3 CAPLUS

CN Propanamide, 2-methyl-N-[2',3',5',6'-tetrafluoro-4'-[6-[(1-methylethyl)amino]-3-pyridinyl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443337-58-4 CAPLUS

CN Methanesulfonamide, N-[2',3',5',6'-tetrafluoro-4'-[6-[(1-methylethyl)amino]-3-pyridinyl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443337-59-5 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 6-methoxy-4'--[(3-methyl-2-butenyl)amino]-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443337-60-8 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 6-methoxy-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-4'-[(2-methylpropyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 443337-61-9 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 4'-[(cyclopropylmethyl)amino]-6-methoxy-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443337-62-0 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 4'-(cyclopentylamino)-6-methoxy-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443337-63-1 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 6-methoxy-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-4'-(propylamino)-, methyl ester (9CI) (CA INDEX NAME)




RN 443337-64-2 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 6-methoxy-5-methyl-4-[6-[(2-methyl-1-oxopropyl)amino]-3-pyridinyl]-4'-[(2-methylpropyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 443337-65-3 CAPLUS

CN 2-Pyridinamine, 5-[4'-[(1H-imidazol-2-ylmethyl)amino]-2,3,5,6-tetramethyl[1,1'-biphenyl]-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443337-66-4 CAPLUS

CN 2-Pyridinamine, 5-[4'-[(1H-imidazol-4-ylmethyl)amino]-2,3,5,6-tetramethyl[1,1'-biphenyl]-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443337-67-5 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 6-methoxy-4-[6-[(methoxycarbonyl)amino]-3-pyridinyl]-5-methyl-4'-[(1-methylethyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 443337-68-6 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 4-[6-(ethylamino)-3-pyridinyl]-6-methoxy-5-methyl-4'-[(1-methylethyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 443337-69-7 CAPLUS

CN 2-Pyridinamine, N-cyclopentyl-5-[3-fluoro-2,5,6-trimethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443337-70-0 CAPLUS

CN 2-Pyridinamine, N-cyclopentyl-5-[4'-[(cyclopropylmethyl)amino]-2,3,5,6-tetramethyl[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443337-71-1 CAPLUS

CN Propanamide, N-[4'-[6-(cyclopentylamino)-3-pyridinyl]-2',3',5',6'-tetramethyl[1,1'-biphenyl]-4-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 443337-72-2 CAPLUS

CN 2-Pyridinamine, N-cyclopentyl-5-[2,3,5,6-tetramethyl-4'-(propylamino)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443337-73-3 CAPLUS

CN 2-Pyridinamine, N-cyclopentyl-5-[2,3,5,6-tetramethyl-4'-[(2-methylpropyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443337-74-4 CAPLUS

CN 2-Pyridinamine, N-cyclopentyl-5-[4'-[(cyclopropylmethyl)amino]-3-fluoro-2,5,6-trimethyl[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443337-75-5 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 2-methyl-4'-[(1-methylethyl)amino]-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443337-76-6 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 2-methyl-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-4'-[(2-methylpropyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 443337-77-7 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 4'-(cyclopentylamino)-2-methyl-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443337-78-8 CAPLUS

CN 2-Propanesulfonamide, N-[4'-[6-(cyclopentylamino)-3-pyridinyl]-2',3',6'-trimethyl[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443337-79-9 CAPLUS

CN 2-Pyridinamine, N-cyclopentyl-5-[2,3,6-trimethyl-4'-[(2-methylpropyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443337-80-2 CAPLUS

CN 2-Pyridinamine, N-cyclopentyl-5-[4'-[(2-furanylmethyl)amino]-2,3,5,6-tetramethyl[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 443337-81-3 CAPLUS


CN [1,1'-Biphenyl]-3-carboxylic acid, 2'-fluoro-6-methoxy-5-methyl-4-[6-[(2-methylpropyl)amino]-3-pyridinyl]-4'-[(phenylmethyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 443337-82-4 CAPLUS


CN [1,1'-Biphenyl]-3-carboxylic acid, 4'-(ethylamino)-6-methoxy-5-methyl-4-[6-(i-butylamino)-3-pyridinyl]- (9CI) (CA INDEX NAME)

[(1-methylethyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443337-83-5 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 6-methoxy-5-methyl-4'-[(1-methylethyl)amino]-4-[6-[(1-methylethyl)(trifluoroacetyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443337-84-6 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 6-methoxy-2-methyl-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-4'-(propylamino)-, methyl ester (9CI) (CA INDEX NAME)




RN 443337-85-7 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 6-methoxy-2-methyl-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-4'-[(2-methylpropyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 443337-86-8 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 6-methoxy-2-methyl-4'-[(3-methyl-2-butenyl)amino]-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443337-87-9 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 4'-[(cyclopropylmethyl)amino]-6-methoxy-2-methyl-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443337-88-0 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 4'-(cyclopentylamino)-6-methoxy-2-methyl-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443337-89-1 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 2,5-dimethyl-4'--[(1-methylethyl)amino]-4-[6-[(2-methylpropyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443337-90-4 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 2,5-dimethyl-4'--[(1-methylethyl)amino]-4-[6-(propylamino)-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443337-91-5 CAPLUS

CN Ethanesulfonamide, N-[2',3',5',6'-tetrafluoro-4'-[6-[(1-methylethyl)amino]-3-pyridinyl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443337-92-6 CAPLUS

CN 2-Pyridinamine, 5-[3-chloro-2,5,6-trimethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 443337-93-7 CAPLUS

CN 2-Pyridinamine, 5-[3-chloro-4'-[(cyclopropylmethyl)amino]-2,5,6-trimethyl[1,1'-biphenyl]-4-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 443337-94-8 CAPLUS

CN 2-Pyridinamine, 5-[3-chloro-4'-[(2-furanylmethyl)amino]-2,5,6-trimethyl[1,1'-biphenyl]-4-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 443337-95-9 CAPLUS

CN 2-Pyridinamine, 5-[3-chloro-4'-(cyclopentylamino)-2,5,6-trimethyl[1,1'-biphenyl]-4-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 443337-96-0 CAPLUS

CN 2-Pyridinamine, 5-[3-chloro-2,5,6-trimethyl-4'-[(2-methylpropyl)amino][1,1'-biphenyl]-4-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 443337-97-1 CAPLUS

CN Methanesulfonamide, N-[3'-chloro-4'-[6-(cyclopentylamino)-3-pyridinyl]-2',5',6'-trimethyl[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443337-98-2 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 4-[6-(cyclopentylamino)-3-pyridinyl]-2,5-dimethyl-4'-[(1-methylethyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 443337-99-3 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 4-[6-[(cyclopropylmethyl)amino]-3-pyridinyl]-2,5-dimethyl-4'--[(1-methylethyl)amino]-, methyl ester (9CI)
(CA INDEX NAME)




RN 443338-01-0 CAPLUS

CN 2-Pyridinamine, 5-[3-chloro-2,5,6-trimethyl-4'--[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 443338-02-1 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 2,5,6-trimethyl-4'--[(1-methylethyl)amino]-4-[6-[(2-methylpropyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443338-03-2 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 6-methyl-4'--[(1-methylethyl)amino]-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443338-04-3 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 6-methyl-4'--[(1-methylethyl)amino]-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-4'--(propylamino)-, methyl ester (9CI) (CA INDEX NAME)




RN 443338-05-4 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 6-methyl-4'--[(1-methylethyl)amino]-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-4'--[(2-methylpropyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 443338-06-5 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 4'-[(cyclopropylmethyl)amino]-6-methyl-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443338-07-6 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 4'-(cyclopentylamino)-6-methyl-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443338-08-7 CAPLUS

CN 2-Pyridinamine, 5-[3-chloro-2,5,6-trimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443338-09-8 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 6-methoxy-2-methyl-4'-[(1-methylethyl)amino]-4-[6-[(2-methylpropyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443338-10-1 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 6-methoxy-2-methyl-4'-[(1-methylethyl)amino]-4-[6-(propylamino)-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443338-11-2 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 4-[6-[(cyclopropylmethyl)amino]-3-pyridinyl]-6-methoxy-2-methyl-4'-[(1-methylethyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 443338-12-3 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 4-[6-(cyclopentylamino)-3-pyridinyl]-6-methoxy-2-methyl-4'-[(1-methylethyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 443338-13-4 CAPLUS

CN 2-Pyridinamine, N-(1-methylethyl)-5-[2,3,5,6-tetrafluoro-4'-[(2-furanylmethyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443338-14-5 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 6-methoxy-4'-[(1-methylethyl)amino]-4-[6-[(2-methylpropyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443338-15-6 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 4-[6-[(cyclopropylmethyl)amino]-3-pyridinyl]-6-methoxy-4'-[(1-methylethyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 443338-16-7 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 4-[6-[(cyclopentylmethyl)amino]-3-pyridinyl]-6-methoxy-4'-[(1-methylethyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 443338-17-8 CAPLUS

CN 2-Pyridinamine, 5-[3-chloro-4'-[(cyclopropylmethyl)amino]-2,5,6-trimethyl[1,1'-biphenyl]-4-yl]-N-(cyclopropylmethyl)- (9CI) (CA INDEX NAME)




RN 443338-18-9 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 4'-[(2,2-dimethyl-1-oxopropyl)amino]-6-methoxy-5-methyl-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443338-19-0 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 4'-[[[(dimethylamino)carbonyl]amino]-6-methoxy-5-methyl-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443338-20-3 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 6-methoxy-5-methyl-4'-[[[(methylamino)carbonyl]amino]-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443338-21-4 CAPLUS

CN 2-Pyridinamine, 5-[3-chloro-2,5,6-trimethyl-4'-[(2-methylpropyl)amino][1,1'-biphenyl]-4-yl]-N-(cyclopropylmethyl)- (9CI) (CA INDEX NAME)




RN 443338-22-5 CAPLUS

CN 2-Pyridinamine, N-(cyclopropylmethyl)-5-[2,3,5,6-tetramethyl-4'-[(2-methylpropyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443338-23-6 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 6-methoxy-4'-[(2-methoxy-2-oxoethyl)amino]-5-methyl-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443338-24-7 CAPLUS

CN 2-Pyridinamine, 5-[3-chloro-4'-[(2-furanylmethyl)amino]-2,5,6-trimethyl[1,1'-biphenyl]-4-yl]-N-(cyclopropylmethyl)- (9CI) (CA INDEX NAME)




RN 443338-25-8 CAPLUS

CN 2-Pyridinamine, 5-[3-chloro-2,5,6-trimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-N-(cyclopropylmethyl)- (9CI) (CA INDEX NAME)




RN 443338-26-9 CAPLUS

CN 2-Pyridinamine, 5-[3'-fluoro-2,3,6-trimethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443338-27-0 CAPLUS

CN Acetamide, N-[5-[2,5-dimethoxy-3,6-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-2-pyridinyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 443338-28-1 CAPLUS

CN Methanesulfonamide, N-[2-fluoro-2',5'-dimethyl-4'-[6-[(1-methylethyl)amino]-3-pyridinyl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443338-29-2 CAPLUS

CN Propanamide, N-[2-fluoro-2',5'-dimethyl-4'-[6-[(1-methylethyl)amino]-3-pyridinyl][1,1'-biphenyl]-4-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 443338-30-5 CAPLUS

CN Carbamic acid, [2-fluoro-2',5'-dimethyl-4'-[6-[(1-methylethyl)amino]-3-pyridinyl][1,1'-biphenyl]-4-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443338-31-6 CAPLUS

CN 2-Pyridinamine, 5-[4'-(cyclopentylamino)-3'-fluoro-2,3,6-trimethyl[1,1'-biphenyl]-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443338-32-7 CAPLUS


CN 2-Pyridinamine, N-(cyclopropylmethyl)-5-[2,3,5,6-tetramethyl-4'-(propylamino)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 443338-33-8 CAPLUS
 CN Propanamide, N-[4'-[6-[(cyclopropylmethyl)amino]-3-pyridinyl]-2',3',5',6'-tetramethyl[1,1'-biphenyl]-4-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 443338-34-9 CAPLUS
 CN 2-Pyridinamine, N-(cyclopropylmethyl)-5-[3'-fluoro-2,3,6-trimethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



IT 443338-35-0P 443338-36-1P 443338-37-2P
 443338-38-3P 443338-39-4P 443338-40-7P
 443338-41-8P 443338-42-9P 443338-43-0P
 443338-44-1P 443338-45-2P 443338-46-3P
 443338-47-4P 443338-48-5P 443338-49-6P
 443338-50-9P 443338-51-0P 443338-53-2P
 443338-54-3P 443338-55-4P 443338-56-5P
 443338-58-7P 443338-59-8P 443338-63-4P
 443338-80-5P 443338-81-6P 443338-82-7P
 443338-83-8P 443338-84-9P 443338-85-0P
 443338-86-1P 443338-87-2P 443338-88-3P
 443338-89-4P 443338-90-7P 443338-91-8P
 443338-92-9P 443338-93-0P 443338-94-1P
 443338-95-2P 443338-96-3P 443338-97-4P
 443338-98-5P 443338-99-6P 443339-00-2P
 443339-01-3P 443339-02-4P 443339-03-5P
 443339-04-6P 443339-05-7P 443339-06-8P
 443339-07-9P 443339-08-0P 443339-09-1P
 443339-10-4P 443339-11-5P 443339-12-6P
 443339-13-7P 443339-14-8P 443339-15-9P
 443339-16-0P 443339-17-1P 443339-18-2P
 443339-19-3P 443339-20-6P 443339-21-7P
 443339-22-8P 443339-23-9P 443339-24-0P
 443339-25-1P 443339-26-2P 443339-27-3P
 443339-28-4P 443339-29-5P 443339-30-8P
 443339-31-9P 443339-32-0P 443339-33-1P
 443339-34-2P 443339-35-3P 443339-36-4P


443339-37-5P 443339-38-6P 443339-39-7P
 443339-40-0P 443339-41-1P 443339-42-2P
 443649-66-9P 443649-67-0P 443649-68-1P
 443649-69-2P 443649-99-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of hetero-tricyclic compds. having substituted amino groups as inhibitors of prodn. of IgE antibody, antiallergic agents, and immunosuppressants)

RN 443338-35-0 CAPLUS


CN Propanamide, N-[4'-[6-(cyclopentylamino)-3-pyridinyl]-2',3',5',6'-tetramethyl[1,1'-biphenyl]-4-yl]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 443338-36-1 CAPLUS

CN 2-Pyridinamine, 5-[3'-fluoro-2,3,6-trimethyl-4'-[(2-methylpropyl)amino][1,1'-biphenyl]-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443338-37-2 CAPLUS

CN 2-Pyridinamine, N-(cyclopropylmethyl)-5-[3'-fluoro-4'-[(2-furanylmethyl)amino]-2,3,6-trimethyl[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443338-38-3 CAPLUS

CN Acetonitrile, [[5-[2'-fluoro-2,5-dimethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




RN 443338-39-4 CAPLUS

CN 2-Pyridinamine, 5-[3'-fluoro-2,3,6-trimethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 443338-40-7 CAPLUS

CN 2-Pyridinamine, 5-[4'-(cyclopentylamino)-3'-fluoro-2,3,6-trimethyl[1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 443338-41-8 CAPLUS

CN Carbamic acid, [5-[2'-fluoro-2,5-dimethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]-2-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443338-42-9 CAPLUS

CN Acetamide, N-[5-[2'-fluoro-2,5-dimethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]-2-pyridinyl]-2-hydroxy- (9CI) (CA INDEX NAME)




RN 443338-43-0 CAPLUS

CN Sulfamide, N-[2-fluoro-2',5'-dimethyl-4'-[6-[(1-methylethyl)amino]-3-pyridinyl][1,1'-biphenyl]-4-yl]-N'-methyl- (9CI) (CA INDEX NAME)




RN 443338-44-1 CAPLUS

CN Ethanesulfonamide, N-[2',3',5',6'-tetrafluoro-4'-[6-[(1-methylethyl)amino]-3-pyridinyl][1,1'-biphenyl]-4-yl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 443338-45-2 CAPLUS
 CN 2-Pyridinamine, 5-[4'-[(cyclopropylmethyl)amino]-3'-fluoro-2,3,6-trimethyl[1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)



RN 443338-46-3 CAPLUS
 CN 2-Pyridinamine, N-cyclopentyl-5-[3'-fluoro-2,3,6-trimethyl-4'-[(2-methylpropyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443338-47-4 CAPLUS
 CN 2-Pyridinamine, 5-[3'-fluoro-2,3,6-trimethyl-4'-[(2-methylpropyl)amino][1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)





RN 443338-48-5 CAPLUS

CN Methanesulfonamide, N-[5-[3'-fluoro-3,6-dimethoxy-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-2-pyridinyl]-N-methyl- (9CI)
(CA INDEX NAME)



RN 443338-49-6 CAPLUS


CN Methanesulfonamide, N-[5-[4'-[(cyclopropylmethyl)amino]-3'-fluoro-3,6-dimethoxy-2,5-dimethyl[1,1'-biphenyl]-4-yl]-2-pyridinyl]-N-methyl- (9CI)
(CA INDEX NAME)



RN 443338-50-9 CAPLUS


CN 2-Pyridinamine, N-cyclopentyl-5-[3'-fluoro-4'-[(2-furanylmethyl)amino]-

2,3,6-trimethyl[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443338-51-0 CAPLUS

CN 2-Pyridinamine, N-cyclopentyl-5-[2,3,5-trimethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443338-53-2 CAPLUS

CN 2-Pyridinamine, N-cyclopentyl-5-[4'-(cyclopentylamino)-2,3,5-trimethyl[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443338-54-3 CAPLUS

CN Urea, [5-[2'-fluoro-2,5-dimethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 443338-55-4 CAPLUS

CN 2-Pyridinamine, 5-[2'-fluoro-2,5-dimethyl-4'-(methylamino)[1,1'-biphenyl]-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443338-56-5 CAPLUS

CN 2-Pyridinamine, 5-[2'-fluoro-2,5-dimethyl-4'-(methylamino)[1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 443338-58-7 CAPLUS

CN 2-Pyridinamine, 5-[3'-fluoro-4'-[(2-furanylmethyl)amino]-2,3,6-trimethyl[1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 443338-59-8 CAPLUS

CN 2-Pyridinamine, N-cyclopentyl-5-[4'-[(2-furanylmethyl)amino]-2,3,5-trimethyl[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443338-63-4 CAPLUS

CN 2-Pyridinamine, N-cyclopentyl-5-[2,3,5-trimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443338-80-5 CAPLUS

CN 2-Pyridinamine, 5-[4'-(2-butynylamino)-3'-fluoro-2-methoxy-3,5-dimethyl[1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)



RN 443338-81-6 CAPLUS


CN Propanamide, N-[4'-[6-[(cyclopropylmethyl)amino]-3-pyridinyl]-2',3',5',6'-tetramethyl[1,1'-biphenyl]-4-yl]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 443338-82-7 CAPLUS

CN 2-Pyridinamine, 5-[4'-[(cyclopropylmethyl)amino]-3'-fluoro-2-methoxy-3,5-dimethyl[1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 443338-83-8 CAPLUS

CN 2-Pyridinamine, 5-[2,5-difluoro-3,6-dimethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443338-84-9 CAPLUS

CN 2-Pyridinamine, 5-[4'-(cyclopentylamino)-2,5-difluoro-3,6-dimethyl[1,1'-biphenyl]-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443338-85-0 CAPLUS

CN 2-Pyridinamine, 5-[2,5-difluoro-3,6-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443338-86-1 CAPLUS

CN 2-Pyridinamine, 5-[2,5-difluoro-3,6-dimethyl-4'-[(2-methylpropyl)amino][1,1'-biphenyl]-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443338-87-2 CAPLUS

CN 2-Pyridinamine, N-(1-methylethyl)-5-[4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443338-88-3 CAPLUS

CN 2-Pyridinamine, 5-[4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443338-89-4 CAPLUS

CN Acetamide, N-methyl-N-[5-[2,3,5,6-tetramethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 443338-90-7 CAPLUS

CN Benzoic acid, 4-[[[2',3',5',6'-tetramethyl-4'-[6-[(1-methylethyl)amino]-3-pyridinyl][1,1'-biphenyl]-4-yl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443338-91-8 CAPLUS

CN Phenol, 3-[[[3-fluoro-2',3',6'-trimethyl-4'-[6-[(3-methyl-2-butenyl)amino]-3-pyridinyl][1,1'-biphenyl]-4-yl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 443338-92-9 CAPLUS

CN Glycine, N-[2',3',5',6'-tetramethyl-4'-[6-[(1-methylethyl)amino]-3-pyridinyl][1,1'-biphenyl]-4-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443338-93-0 CAPLUS

CN 2-Pyridinamine, N-(cyclopropylmethyl)-5-[4'-[(cyclopropylmethyl)amino]-3'-fluoro-2-methoxy-3,5,6-trimethyl[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443338-94-1 CAPLUS

CN Glycine, N-[2',3',5',6'-tetramethyl-4'-[6-[(1-methylethyl)amino]-3-pyridinyl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443338-95-2 CAPLUS

CN Phenol, 4-[[[2',3',5',6'-tetramethyl-4'-[6-[(1-methylethyl)amino]-3-pyridinyl][1,1'-biphenyl]-4-yl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 443338-96-3 CAPLUS

CN 2-Pyridinamine, N-(1-methylethyl)-5-[2,3',5-trifluoro-3,6-dimethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443338-97-4 CAPLUS

CN 2-Pyridinamine, 5-[4'-(cyclopentylamino)-2,3',5-trifluoro-3,6-dimethyl[1,1'-biphenyl]-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443338-98-5 CAPLUS

CN 2-Pyridinamine, 5-[4'-[(cyclopropylmethyl)amino]-2,3',5-trifluoro-3,6-dimethyl[1,1'-biphenyl]-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443338-99-6 CAPLUS

CN 2-Pyridinamine, N-(1-methylethyl)-5-[2,3',5-trifluoro-4'-[(2-furanylmethyl)amino]-3,6-dimethyl[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443339-00-2 CAPLUS

CN 2-Pyridinamine, N-(1-methylethyl)-5-[2,3',5-trifluoro-3,6-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443339-01-3 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3',6-trifluoro-4'-[(3-methyl-2-butenyl)amino]-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443339-02-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 3,3',6-trifluoro-4'-[(1-methylethyl)amino]-4-[6-[(1-methylethyl)amino]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 443339-03-5 CAPLUS

CN 2-Pyridinamine, N-(2-methylpropyl)-5-[2,3',5-trifluoro-3,6-dimethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443339-04-6 CAPLUS

CN 2-Pyridinamine, N-(2-methylpropyl)-5-[2,3',5-trifluoro-3,6-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443339-05-7 CAPLUS

CN 2-Pyridinamine, 5-[4'-[(cyclopropylmethyl)amino]-2,3',5-trifluoro-3,6-dimethyl[1,1'-biphenyl]-4-yl]-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 443339-06-8 CAPLUS

CN 2-Pyridinamine, 5-[3,3'-difluoro-2,5,6-trimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 443339-07-9 CAPLUS

CN 2-Pyridinamine, 5-[3,3'-difluoro-2,5,6-trimethyl-4'-[(2-methylpropyl)amino][1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 443339-08-0 CAPLUS

CN 2-Pyridinamine, 5-[3,3'-difluoro-2,5,6-trimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443339-09-1 CAPLUS

CN 2-Pyridinamine, 5-[3,3'-difluoro-2,5,6-trimethyl-4'-[(2-methylpropyl)amino][1,1'-biphenyl]-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443339-10-4 CAPLUS

CN 2-Pyridinamine, 5-[3,3'-difluoro-2,5,6-trimethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443339-11-5 CAPLUS

CN 2-Pyridinamine, 5-[3,3'-difluoro-2,5,6-trimethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 443339-12-6 CAPLUS

CN 2-Pyridinamine, N-(3-methyl-2-butenyl)-5-[2,3',5-trifluoro-3,6-dimethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443339-13-7 CAPLUS

CN 2-Pyridinamine, 5-[4'-(cyclopentylamino)-2,3',5-trifluoro-3,6-dimethyl[1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 443339-14-8 CAPLUS

CN 2-Pyridinamine, 5-[2-chloro-3'-fluoro-3,5,6-trimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443339-15-9 CAPLUS

CN 2-Pyridinamine, 5-[2-chloro-3'-fluoro-3,5,6-trimethyl-4'-[(2-methylpropyl)amino][1,1'-biphenyl]-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443339-16-0 CAPLUS

CN 2-Pyridinamine, 5-[3'-fluoro-2,3,5,6-tetramethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443339-17-1 CAPLUS

CN 2-Pyridinamine, 5-[3'-fluoro-2,3,5,6-tetramethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443339-18-2 CAPLUS

CN 2-Pyridinamine, N-(3-methyl-2-butenyl)-5-[2,3',5-trifluoro-3,6-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443339-19-3 CAPLUS

CN 2-Pyridinamine, 5-[4'-[(cyclopropylmethyl)amino]-2,3',5-trifluoro-3,6-dimethyl[1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 443339-20-6 CAPLUS

CN 2-Pyridinamine, N-(3-methyl-2-butenyl)-5-[2,3',5-trifluoro-4'-[(2-furanylmethyl)amino]-3,6-dimethyl[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443339-21-7 CAPLUS

CN 2-Pyridinamine, 5-[2-chloro-3'-fluoro-3,5,6-trimethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443339-22-8 CAPLUS

CN 2-Pyridinamine, 5-[2-chloro-3'-fluoro-3,5,6-trimethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 443339-23-9 CAPLUS

CN 2-Pyridinamine, 5-[2-chloro-3'-fluoro-3,5,6-trimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 443339-24-0 CAPLUS

CN 2-Pyridinamine, 5-[2-chloro-3'-fluoro-3,5,6-trimethyl-4'-[(2-methylpropyl)amino][1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 443339-25-1 CAPLUS

CN 2-Pyridinamine, 5-[3'-fluoro-4'-[(2-methoxyethyl)amino]-2,3,5,6-tetramethyl[1,1'-biphenyl]-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443339-26-2 CAPLUS

CN 2-Pyridinamine, 5-[3'-fluoro-2,3,5,6-tetramethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 443339-27-3 CAPLUS

CN 2-Pyridinamine, 5-[3'-fluoro-2,3,5,6-tetramethyl-4'-[(2-methylpropyl)amino][1,1'-biphenyl]-4-yl]-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 443339-28-4 CAPLUS

CN 2-Pyridinamine, 5-[3,3'-difluoro-2,5,6-trimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 443339-29-5 CAPLUS

CN 2-Pyridinamine, 5-[3'-fluoro-2,3,5-trimethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443339-30-8 CAPLUS

CN 2-Pyridinamine, 5-[4'-(cyclopentylamino)-3'-fluoro-2,3,5-trimethyl[1,1'-biphenyl]-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443339-31-9 CAPLUS

CN 2-Pyridinamine, 5-[3-chloro-3'-fluoro-2,5,6-trimethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 443339-32-0 CAPLUS

CN 2-Pyridinamine, 5-[3-chloro-3'-fluoro-2,5,6-trimethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443339-33-1 CAPLUS

CN 2-Pyridinamine, 5-[3-chloro-3'-fluoro-2,5,6-trimethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 443339-34-2 CAPLUS

CN 2-Pyridinamine, 5-[3'-fluoro-2,3,5-trimethyl-4'-[(2-methylpropyl)amino][1,1'-biphenyl]-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443339-35-3 CAPLUS

CN 2-Pyridinamine, 5-[3'-fluoro-2,3,5-trimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443339-36-4 CAPLUS

CN Propanamide, N-[3-fluoro-2',3',5',6'-tetramethyl-4'-[6-[(2-methylpropyl)amino]-3-pyridinyl][1,1'-biphenyl]-4-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 443339-37-5 CAPLUS

CN Carbamic acid, [3-fluoro-2',3',5',6'-tetramethyl-4'-[6-[(2-methylpropyl)amino]-3-pyridinyl][1,1'-biphenyl]-4-yl]-, methyl ester (9CI)
(CA INDEX NAME)




RN 443339-38-6 CAPLUS

CN Carbamic acid, [3-fluoro-2',3',5',6'-tetramethyl-4'-[6-[(1-methylethyl)amino]-3-pyridinyl][1,1'-biphenyl]-4-yl]-, methyl ester (9CI)
(CA INDEX NAME)



RN 443339-39-7 CAPLUS


CN Glycine, N-[2',3',5',6'-tetramethyl-4'-[6-[(1-methylethyl)amino]-3-pyridinyl][1,1'-biphenyl]-4-yl]-, methyl ester, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 443339-40-0 CAPLUS

CN 2-Pyridinamine, 5-[2-chloro-3'-fluoro-3,5,6-trimethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 443339-41-1 CAPLUS

CN 2-Pyridinamine, 5-[2-chloro-3'-fluoro-3,5,6-trimethyl-4'-[(2-methylpropyl)amino][1,1'-biphenyl]-4-yl]-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 443339-42-2 CAPLUS

CN 2-Pyridinamine, 5-[2-chloro-3'-fluoro-3,5,6-trimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 443649-66-9 CAPLUS

CN 2-Pyridinamine, 5-(4'-amino-2,5-dimethoxy-3,6-dimethyl[1,1'-biphenyl]-4-yl)-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 443649-67-0 CAPLUS

CN 2-Pyridinamine, 5-(4'-amino-2,5-dimethoxy-3,6-dimethyl[1,1'-biphenyl]-4-yl)-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 443649-68-1 CAPLUS

CN 2-Pyridinamine, N-(1-methylethyl)-5-[2,3,5,6-tetramethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 443649-69-2 CAPLUS

CN 2-Pyridinamine, 5-[2,5-dimethoxy-3,6-dimethyl-4'-[(2-methylpropyl)amino][1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI)
(CA INDEX NAME)



RN 443649-99-8 CAPLUS

CN 2-Pyridinamine, N-(1-methylethyl)-5-[2,3,6-trimethyl-4'-[(1-methylethyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L37 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:78356 CAPLUS
 DN 134:131548
 TI Preparation of tricyclic compounds as allergy inhibitors,
immunosuppressants, and IgE production inhibitors
 IN Tanimoto, Norihiko; Inagaki, Masanao
 PA Shionogi & Co., Ltd., Japan
 SO PCT Int. Appl., 363 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001007401	A1	20010201	WO 2000-JP4726	20000714
	W:		AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
	AU 2000060160	A5	20010213	AU 2000-60160	20000714
PRAI	JP 1999-209298	A	19990723		
	JP 1999-211702	A	19990727		
	WO 2000-JP4726	W	20000714		


← Common Sp.

OS MARPAT 134:131548
 AB The title compds. I [A, B and C are each an arom. carbo- or hetero-cycle or the like, with the proviso that when A is an optionally substituted five-membered heterocycle, W1 is a bond, the same applying in the case of B and W2 and that of C and W3; X and X' are each O, NH, or the like; Y is lower alkyl, lower alkenyl, or the like; V1 and V2 are each a single bond or the like; Ra and Rb are each hydrogen, lower alkyl, lower alkenyl, or the like; further details on Ra and Rb are given; n is 0 to 2] are prepd. Several compds. of this invention at 40 mg/kg/day orally for 10 days suppressed the prodn. of IgE in a mouse model. Formulations are given.

IT 321438-90-8P 321981-93-5P 321981-94-6P
 321981-97-9P 321981-98-0P 321981-99-1P
 321982-00-7P 321982-01-8P 321982-08-5P
 321982-09-6P 321982-10-9P 321982-11-0P
 321982-12-1P 321982-13-2P 321982-29-0P
 321982-31-4P 321982-32-5P 321982-33-6P
 321982-35-8P 321982-36-9P 321982-38-1P
 321982-39-2P 321982-40-5P 321982-41-6P
 321982-42-7P 321982-43-8P 321982-48-3P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of tricyclic compds. as allergy inhibitors,
immunosuppressants, and IgE prodn. inhibitors)

RN 321438-90-8 CAPLUS
 CN 2(1H)-Pyridinone, 5-[2'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-, (1-methylethylidene)hydrazone (9CI)
 (CA INDEX NAME)




RN 321981-93-5 CAPLUS

CN 2-Propanone, O-[5-[2'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-2-pyridinyl]oxime (9CI) (CA INDEX NAME)




RN 321981-94-6 CAPLUS

CN 3-Pentanone, O-[5-[2'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-2-pyridinyl]oxime (9CI) (CA INDEX NAME)




RN 321981-97-9 CAPLUS

CN 2-Butanone, O-[5-[2'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-2-pyridinyl]oxime (9CI) (CA INDEX NAME)




RN 321981-98-0 CAPLUS

CN Ethanimidic acid, N-[[5-[2'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-2-pyridinyl]oxy]-, ethyl ester (9CI)
(CA INDEX NAME)




RN 321981-99-1 CAPLUS

CN Cyclopentanone, O-[5-[2'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-2-pyridinyl]oxime (9CI) (CA INDEX NAME)




RN 321982-00-7 CAPLUS

CN Cyclohexanone, O-[5-[2'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-2-pyridinyl]oxime (9CI) (CA INDEX NAME)




RN 321982-01-8 CAPLUS

CN Ethanone, 1-phenyl-, O-[5-[2'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-2-pyridinyl]oxime (9CI) (CA INDEX NAME)




RN 321982-08-5 CAPLUS

CN 2-Propanone, O-[5-(4'-amino-2'-fluoro-2,5-dimethyl[1,1'-biphenyl]-4-yl)-2-pyridinyl]oxime (9CI) (CA INDEX NAME)




RN 321982-09-6 CAPLUS

CN 2-Propanone, O-[5-[4'-(cyclohexylamino)-2'-fluoro-2,5-dimethyl[1,1'-biphenyl]-4-yl]-2-pyridinyl]oxime (9CI) (CA INDEX NAME)



RN 321982-10-9 CAPLUS


CN 2-Propanone, O-[5-[2'-fluoro-2,5-dimethyl-4'-[(phenylmethyl)amino][1,1'-biphenyl]-4-yl]-2-pyridinyl]oxime (9CI) (CA INDEX NAME)



RN 321982-11-0 CAPLUS


CN 2-Propanone, O-[5-[2,3,5,6-tetramethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-2-pyridinyl]oxime (9CI) (CA INDEX NAME)

biphenyl]-4-yl]-2-pyridinyl]oxime (9CI) (CA INDEX NAME)




RN 321982-12-1 CAPLUS

CN Ethanone, 1-phenyl-, O-[5-[2,3,5,6-tetramethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-2-pyridinyl]oxime (9CI) (CA INDEX NAME)




RN 321982-13-2 CAPLUS

CN Ethanimidic acid, N-[[5-[2,3,5,6-tetramethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-2-pyridinyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 321982-29-0 CAPLUS

CN 2-Propanone, O-[5-[3'-fluoro-2,3,5,6-tetramethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-2-pyridinyl]oxime (9CI) (CA INDEX NAME)




RN 321982-31-4 CAPLUS

CN 2-Propanone, O-[5-[2-hydroxy-3,5,6-trimethyl-4'-[[[(1-methylethylidene)amino]oxy]methyl][1,1'-biphenyl]-4-yl]-2-pyridinyl]oxime (9CI) (CA INDEX NAME)




RN 321982-32-5 CAPLUS

CN 2-Propanone, O-[5-[3-hydroxy-2,5,6-trimethyl-4'-[[[(1-methylethylidene)amino]oxy]methyl][1,1'-biphenyl]-4-yl]-2-pyridinyl]oxime (9CI) (CA INDEX NAME)




RN 321982-33-6 CAPLUS

CN 2-Propanone, O-[5-[3-hydroxy-2,5-dimethoxy-4'-[[[(1-methylethylidene)amino]oxy]methyl][1,1'-biphenyl]-4-yl]-2-pyridinyl]oxime (9CI) (CA INDEX NAME)




RN 321982-35-8 CAPLUS

CN Propanal, 2-methyl-, [5-[2'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-2-pyridinyl]hydrazone (9CI) (CA INDEX NAME)




RN 321982-36-9 CAPLUS

CN 2-Butenal, 3-methyl-, [5-[2'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-2-pyridinyl]hydrazone (9CI) (CA INDEX NAME)




RN 321982-38-1 CAPLUS

CN 2(1H)-Pyridinone, 5-[2'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-, hydrazone (9CI) (CA INDEX NAME)




RN 321982-39-2 CAPLUS

CN 2(1H)-Pyridinone, 5-[2'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-, (2-methylpropyl)hydrazone (9CI) (CA INDEX NAME)




RN 321982-40-5 CAPLUS

CN 2(1H)-Pyridinone, 5-[2'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-, (3-methyl-2-butenyl)hydrazone (9CI) (CA INDEX NAME)




RN 321982-41-6 CAPLUS

CN Hydrazinecarboxylic acid, 2-[5-[2'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 321982-42-7 CAPLUS

CN Acetic acid, 2-[5-[2'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-2-pyridinyl]hydrazide (9CI) (CA INDEX NAME)




RN 321982-43-8 CAPLUS

CN Hydrazinecarboxylic acid, 2-[5-[2'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 321982-48-3 CAPLUS

CN Propanoic acid, 2-methyl-, 2-[5-[2'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-2-pyridinyl]hydrazide (9CI) (CA INDEX NAME)




IT **321438-83-9P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of tricyclic compds. as allergy inhibitors, immunosuppressants, and IgE prodn. inhibitors)

RN 321438-83-9 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2-fluoro-2',5'-dimethyl-4'-[6-(methylthio)-3-pyridinyl]-. (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L37 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:63977 CAPLUS
 DN 134:116240
 TI Preparation of tricyclic compounds bearing acyloxymethoxycarbonyl pendants
 as prodrugs for allergy inhibitors and **immunosuppressants**
 IN Aono, Katsutoshi; Ichihashi, Teruhisa; Kugimiya, Akira
 PA Shionogi + Co., Ltd., Japan
 SO PCT Int. Appl., 103 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001005768	A1	20010125	WO 2000-JP4724	20000714
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 2000060158	A5	20010205	AU 2000-60158	20000714
	EP 1219606	A1	20020703	EP 2000-946315	20000714
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
PRAI	JP 1999-204977	A	19990719		
	JP 1999-211702	A	19990727		
	JP 2000-84052	A	20000324		
	WO 2000-JP4724	W	20000714		
OS	MARPAT 134:116240				
AB	<p>Compds. of general formula (I) and their salts and solvates of both [wherein one of X and X1 is -N(CO2CR3R2O2CR1)- and the other is (CH2)s, O, NRA, -N(CO2CR3R2O2CR1), or S(O)p (wherein s and p is 0-2; R1 is lower alkyl substituted with carbamoyl, lower alkylcarbamoyl, carbamoyloxy, lower alkylcarbamoyloxy, acetyl amino, or the like; and R2 and R3 are each hydrogen or lower alkyl); Y and Y1 are each optionally substituted lower alkyl, lower alkenyl, or lower alkynyl, cycloalkyl, cycloalkenyl, lower alkoxy carbonyl, the like; ring A, B and C are each an optionally substituted arom. carbocycle or an optionally substituted optionally benzene-fused 5- or 6-membered heterocycle; when ring A, B and C are optionally substituted 5-membered heterocyclic ring, W1, W2, and W3 are each a bond; and when both V1 and V2 are each a single bond, at least one ring A, B, and C is an arom. carbocyclic ring and at least one of them is a optionally substituted optionally benzene-fused 5- to 6-membered heterocycle], which are prodrugs for allergy inhibitors and immunosuppressants with improved oral absorbability, are prepd. These compds. suppress mitogenic and/or cytokine reactions and possess immunosuppressant and antiallergic activity, and their activated compds. in particular possess very potent inhibitory activity against proliferation of T and B cells and/or antibody-prodn. inhibitory activity. Thus, acylation of 3-(4'-amino-1,1'-biphenyl-4-yl)pyridine deriv. (II; R = H) with chloromethyl chloroformate in the presence of Et3N in Et2O at 0.degree. to room temp. for 4 h gave II (R = CO2CH2Cl) which was condensed with succinamic acid in the presence of K2CO3 and KBr in DMF with vigorously stirring at room temp. for 20 h gave II (R =</p>				

CO₂CH₂O₂CCH₂CH₂CONH₂) (III). III and II (R = Ac-Gly-Gly-OCH₂O₂C) were in vivo effective for inhibiting anti-ovalbumin antibody prodn. in rats with passive cutaneous anaphylaxis (PCA) reaction value of 0.8 and <0, resp., at 10 mg/kg p.o. vs. 6.7 for II (R = H).

IT **321439-02-5P**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of tricyclic compds. bearing acyloxymethoxycarbonyl pendants as prodrugs for allergy inhibitors and **immunosuppressants**)

RN 321439-02-5 CAPLUS

CN Butanoic acid, 4-amino-4-oxo-, [[[[5-[3'-fluoro-2,5-dimethoxy-3,6-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-3-pyridinyl](3-methyl-2-butenyl)amino]carbonyl]oxy]methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

=CMe₂


IT **234429-28-8P 321438-83-9P 321438-84-0P
321438-85-1P 321438-90-8P 321438-95-3P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of tricyclic compds. bearing acyloxymethoxycarbonyl pendants as prodrugs for allergy inhibitors and **immunosuppressants**)


RN 234429-28-8 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2-fluoro-2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 321438-83-9 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2-fluoro-2',5'-dimethyl-4'-[6-(methylthio)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 321438-84-0 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[2-fluoro-2',5'-dimethyl-4'-[6-(methylthio)-3-pyridinyl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 321438-85-1 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[2-fluoro-2',5'-dimethyl-4'-[6-(methylsulfonyl)-3-pyridinyl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 321438-90-8 CAPLUS

CN 2(1H)-Pyridinone, 5-[2'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-, (1-methylethylidene)hydrazone (9CI)
(CA INDEX NAME)



RN 321438-95-3 CAPLUS

CN Carbamic acid, [5-[3'-fluoro-2,5-dimethoxy-3,6-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-3-pyridinyl] (3-methyl-2-butenyl)-, chloromethyl ester (9CI) (CA INDEX NAME)



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L37 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1999:495258 CAPLUS
 DN 131:129907
 TI Preparation and formulation of tricyclic compounds as
immunosuppressants and allergy inhibitors
 IN Tanimoto, Norihiko; Hasegawa, Yasushi; Haga, Nobuhiro
 PA Shionogi & Co., Ltd., Japan
 SO PCT Int. Appl., 298 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9938829	A1	19990805	WO 1999-JP297	19990126
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2318368	AA	19990805	CA 1999-2318368	19990126
	AU 9919837	A1	19990816	AU 1999-19837	19990126
	AU 742641	B2	20020110		
	EP 1052238	A1	20001115	EP 1999-900676	19990126
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	BR 9908539	A	20001205	BR 1999-8539	19990126
	NZ 506101	A	20030630	NZ 1999-506101	19990126
	RU 2216533	C2	20031120	RU 2000-121556	19990126
	NO 2000003706	A	20000914	NO 2000-3706	20000719
	US 6562817	B1	20030513	US 2000-600790	20000721
PRAI	JP 1998-15554	A	19980128		
	WO 1999-JP297	W	19990126		

OS MARPAT 131:129907

AB The title compds. I [each of ring A, ring B and ring C is independently a substituted or unsubstituted arom. ring or a substituted or unsubstituted five or six-membered heterocycle which may be condensed with a benzene ring; when ring A, ring B and/or ring C is a substituted or unsubstituted five-membered heterocycle, W1, W2 and/or W3 represents a bond; X is O or NR1 (where R1 is hydrogen, a lower alkyl or the like); Y is hydrogen, a lower alkyl, a lower alkenyl or the like; one of V1 and V2 is a single bond and the other is a single bond, O, etc.] are prepd. The title compd. II in vitro showed IC50 of 400 ng/mL against the growth of mouse EL4 cells. The inhibiting activities of compds. of this invention against the prodn. of IgE were also demonstrated.

IT 234429-34-6P 234429-35-7P 234429-36-8P

234429-37-9P 234429-38-0P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of tricyclic compds. as **immunosuppressants** and allergy inhibitors)

RN 234429-34-6 CAPLUS


CN [1,1'-Biphenyl]-2,3'-diol, 3,6-dimethoxy-4-(5-nitro-2-pyridinyl)-4'-

(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 234429-35-7 CAPLUS

CN [1,1'-Biphenyl]-2,3'-diol, 3,6-dimethoxy-4-(5-nitro-2-pyridinyl)-4'-(phenylmethoxy)-, dimethanesulfonate (ester) (9CI) (CA INDEX NAME)




RN 234429-36-8 CAPLUS

CN [1,1'-Biphenyl]-2,3'-diol, 4-(5-amino-2-pyridinyl)-3,6-dimethoxy-4'-(phenylmethoxy)-, dimethanesulfonate (ester) (9CI) (CA INDEX NAME)




RN 234429-37-9 CAPLUS

CN Acetamide, N-[6-[3,6-dimethoxy-2,3'-bis[(methanesulfonyl)oxy]-4'-(phenylmethoxy)[1,1'-biphenyl]-4-yl]-3-pyridinyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)



RN 234429-38-0 CAPLUS

CN Acetamide, N-[6-[3,6-dimethoxy-4'-[(3-methyl-2-butenyl)oxy]-2,3'-bis[(methylsulfonyl)oxy][1,1'-biphenyl]-4-yl]-3-pyridinyl]-2,2,2-trifluoro-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




IT 234423-85-9P 234425-81-1P 234425-82-2P
 234425-83-3P 234425-86-6P 234425-89-9P
 234425-90-2P 234425-91-3P 234425-92-4P
 234425-94-6P 234425-95-7P 234426-02-9P
 234426-03-0P 234426-04-1P 234426-06-3P
 234426-07-4P 234426-27-8P 234426-28-9P
 234426-29-0P 234426-30-3P 234426-31-4P
 234426-32-5P 234426-33-6P 234426-34-7P
 234426-35-8P 234426-36-9P 234426-37-0P
 234426-38-1P 234426-39-2P 234426-42-7P
 234426-44-9P 234426-45-0P 234426-46-1P
 234426-48-3P 234426-49-4P 234426-50-7P
 234426-51-8P 234426-52-9P 234426-53-0P
 234426-54-1P 234426-55-2P 234426-56-3P
 234426-57-4P 234426-58-5P 234426-59-6P
 234426-60-9P 234426-61-0P 234426-62-1P
 234426-63-2P 234426-65-4P 234426-66-5P
 234426-67-6P 234426-68-7P 234426-69-8P
 234426-70-1P 234426-71-2P 234426-72-3P
 234426-73-4P 234426-74-5P 234426-75-6P
 234426-76-7P 234426-77-8P 234426-78-9P
 234426-79-0P 234426-80-3P 234426-81-4P
 234426-82-5P 234426-85-8P 234426-86-9P
 234426-87-0P 234426-88-1P 234426-89-2P
 234426-90-5P 234426-91-6P 234426-92-7P
 234426-93-8P 234426-94-9P 234426-95-0P
 234426-96-1P 234426-97-2P 234426-98-3P
 234426-99-4P 234427-00-0P 234427-01-1P
 234427-02-2P 234427-03-3P 234427-04-4P

234427-05-5P 234427-06-6P 234427-07-7P
 234427-08-8P 234427-09-9P 234427-10-2P
 234427-11-3P 234427-12-4P 234427-13-5P
 234427-14-6P 234427-15-7P 234427-16-8P
 234427-17-9P 234427-18-0P 234427-19-1P
 234427-20-4P 234427-21-5P 234427-22-6P
 234427-23-7P 234427-24-8P 234427-25-9P
 234427-26-0P 234427-27-1P 234427-28-2P
 234427-29-3P 234427-30-6P 234427-31-7P
 234427-32-8P 234427-33-9P 234427-35-1P
 234427-36-2P 234427-37-3P 234427-39-5P
 234427-40-8P 234427-41-9P 234427-42-0P
 234427-43-1P 234427-44-2P 234427-45-3P
 234427-46-4P 234427-47-5P 234427-48-6P
 234427-49-7P 234427-50-0P 234427-51-1P
 234427-52-2P 234427-53-3P 234427-54-4P
 234427-55-5P 234427-56-6P 234427-57-7P
 234427-58-8P 234427-59-9P 234427-60-2P
 234427-61-3P 234427-62-4P 234427-63-5P
 234427-64-6P 234427-65-7P 234427-66-8P
 234427-67-9P 234427-68-0P 234427-69-1P
 234427-71-5P 234427-72-6P 234427-73-7P
 234427-74-8P 234427-75-9P 234427-76-0P
 234427-77-1P 234427-78-2P 234427-79-3P
 234427-80-6P 234427-81-7P 234427-82-8P
 234427-83-9P 234427-84-0P 234427-85-1P
 234427-86-2P 234427-87-3P 234427-88-4P
 234427-89-5P 234427-90-8P 234427-91-9P
 234427-92-0P 234427-93-1P 234427-94-2P
 234427-95-3P 234427-96-4P 234427-97-5P
 234427-98-6P 234427-99-7P 234428-00-3P
 234428-54-7P 234428-55-8P 234428-56-9P
 234428-57-0P 234428-58-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of tricyclic compds. as **immunosuppressants** and allergy inhibitors)


RN 234423-85-9 CAPLUS

CN [1,1'-Biphenyl]-2,3'-diol, 3,6-dimethoxy-4-[5-[(3-methyl-2-butenyl)amino]-2-pyridinyl]-4'-[(3-methyl-2-butenyl)oxy]- (9CI) (CA INDEX NAME)




RN 234425-81-1 CAPLUS

CN [1,1'-Biphenyl]-2,3'-diol, 3,6-dimethoxy-4'-[(3-methyl-2-butenyl)oxy]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 234425-82-2 CAPLUS

CN Pyridine, 2-[3'-methoxy-2,5-dimethyl-4'-[(3-methyl-2-butenyl)oxy]]-1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 234425-83-3 CAPLUS

CN 3-Pyridinamine, 6-[3'-methoxy-2,5-dimethyl-4'-[(3-methyl-2-butenyl)oxy]]-1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 234425-86-6 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[6-[3'-methoxy-2,5-dimethyl-4'-[(3-methyl-2-butenyl)oxy]]-1,1'-biphenyl-4-yl]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234425-89-9 CAPLUS

CN [1,1'-Biphenyl]-2,3'-diol, 4-[5-(dimethylamino)-2-pyridinyl]-3,6-dimethoxy-4'-(phenylmethoxy)-, dimethanesulfonate (ester) (9CI) (CA INDEX NAME)




RN 234425-90-2 CAPLUS

CN [1,1'-Biphenyl]-2,3'-diol, 4-[5-(dimethylamino)-2-pyridinyl]-3,6-dimethoxy-4'-(3-methyl-2-butenyloxy)- (9CI) (CA INDEX NAME)




RN 234425-91-3 CAPLUS

CN [1,1'-Biphenyl]-2,3'-diol, 4-[5-(dimethylamino)-2-pyridinyl]-3,6-dimethoxy-4'-(3-methyl-2-butenyloxy)-, dimethanesulfonate (ester) (9CI) (CA INDEX NAME)




RN 234425-92-4 CAPLUS

CN 3-Pyridinamine, 6-[3'-methoxy-2,5-dimethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 234425-94-6 CAPLUS

CN [1,1'-Biphenyl]-2,3'-diol, 3,6-dimethoxy-4'-[(3-methyl-2-butenyl)oxy]-4-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 234425-95-7 CAPLUS

CN Pyridine, 3-[3'-methoxy-2,5-dimethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 234426-02-9 CAPLUS

CN [1,1'-Biphenyl]-2,3'-diol, 4-[6-(dimethylamino)-3-pyridinyl]-3,6-dimethoxy-4'-(phenylmethoxy)-, dimethanesulfonate (ester) (9CI) (CA INDEX NAME)




RN 234426-03-0 CAPLUS

CN [1,1'-Biphenyl]-2,3'-diol, 4-[6-(dimethylamino)-3-pyridinyl]-3,6-dimethoxy-4'-(3-methyl-2-butenyl)oxy-, dimethanesulfonate (ester) (9CI) (CA INDEX NAME)




RN 234426-04-1 CAPLUS

CN [1,1'-Biphenyl]-2,3'-diol, 4-[6-(dimethylamino)-3-pyridinyl]-3,6-dimethoxy-4'-(3-methyl-2-butenyl)oxy-, dimethanesulfonate (ester) (9CI) (CA INDEX NAME)




RN 234426-06-3 CAPLUS

CN [1,1'-Biphenyl]-2,3'-diol, 3,6-dimethoxy-4'-[(3-methyl-2-butenyl)oxy]-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 234426-07-4 CAPLUS

CN Pyridine, 4-[3'-methoxy-2,5-dimethyl-4'-(phenylmethoxy)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 234426-27-8 CAPLUS

CN 3-Pyridinamine, 6-[3'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 234426-28-9 CAPLUS

CN 3-Pyridinamine, 6-[3'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 234426-29-0 CAPLUS

CN Pyridine, 2-[3'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]-5-nitro- (9CI) (CA INDEX NAME)




RN 234426-30-3 CAPLUS

CN Pyridine, 2-[2,5-dimethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 234426-31-4 CAPLUS

CN Pyridine, 2-[3'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 234426-32-5 CAPLUS

CN 3-Pyridinamine, N-cyclohexyl-6-[3'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 234426-33-6 CAPLUS

CN Pyridine, 2-[3'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]-5-methoxy- (9CI) (CA INDEX NAME)




RN 234426-34-7 CAPLUS

CN Pyridine, 2-[3'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]-5-[(3-methyl-2-butenyl)oxy]- (9CI) (CA INDEX NAME)




RN 234426-35-8 CAPLUS

CN 3-Pyridinamine, 6-[3'-fluoro-2,3,5,6-tetramethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 234426-36-9 CAPLUS

CN 3-Pyridinamine, 6-[3'-fluoro-2,3,5,6-tetramethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 234426-37-0 CAPLUS

CN 3-Pyridinol, 6-[3'-fluoro-2,3,5,6-tetramethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 234426-38-1 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2-fluoro-2',5'-dimethoxy-4'-[6-[(3-methyl-2-butenyl)oxy]]-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 234426-39-2 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2-fluoro-2',5'-dimethoxy-4'-[6-[(3-methyl-2-butenyl)oxy]]-3-pyridinyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 234426-42-7 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2-fluoro-2',5'-dimethoxy-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]]-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 234426-44-9 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2-fluoro-2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234426-45-0 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2-fluoro-2',5'-dimethyl-4'-[5-[(3-methyl-2-butenyl)oxy]-2-pyridinyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 234426-46-1 CAPLUS

CN [1,1'-Biphenyl]-4-amine, N-cyclohexyl-2-fluoro-2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234426-48-3 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2-chloro-N-(cyclohexylmethyl)-2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234426-49-4 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2-chloro-N-cyclohexyl-2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234426-50-7 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2-chloro-2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234426-51-8 CAPLUS

CN [1,1'-Biphenyl]-4-amine, N-cyclopentyl-2-fluoro-2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234426-52-9 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2-fluoro-2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 234426-53-0 CAPLUS

CN [1,1'-Biphenyl]-4-amine, N-[(4-ethylphenyl)methyl]-2-fluoro-2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234426-54-1 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2-fluoro-2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-N-[[4-(1-methylethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 234426-55-2 CAPLUS

CN Benzoic acid, 4-[[[2-fluoro-2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl][1,1'-biphenyl]-4-yl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 234426-56-3 CAPLUS

CN Benzoic acid, 4-[[[2-fluoro-2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl][1,1'-biphenyl]-4-yl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 234426-57-4 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2,2',5'-trimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234426-58-5 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234426-59-6 CAPLUS


CN [1,1'-Biphenyl]-4-amine, 2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-N-2-propynyl- (9CI) (CA INDEX NAME)



RN 234426-60-9 CAPLUS


CN [1,1'-Biphenyl]-4-amine, N-(cyclohexylmethyl)-2',5'-dimethyl-4'-[6-[(3-

methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234426-61-0 CAPLUS

CN [1,1'-Biphenyl]-4-amine, N-cyclohexyl-2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234426-62-1 CAPLUS

CN 4-Pyridinemethanamine, N-[2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 234426-63-2 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 234426-65-4 CAPLUS

CN 3-Thiophenemethanamine, N-[2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 234426-66-5 CAPLUS

CN 3-Furanmethanamine, N-[2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 234426-67-6 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234426-68-7 CAPLUS

CN [1,1'-Biphenyl]-4-amine, N,2',5'-trimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234426-69-8 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2',3,5'-trimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234426-70-1 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2',3,5'-trimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 234426-71-2 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 3-fluoro-2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234426-72-3 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 3-fluoro-2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 234426-73-4 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 3-chloro-2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234426-74-5 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 3-chloro-2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 234426-75-6 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 3-methoxy-2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234426-76-7 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 3-methoxy-2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 234426-77-8 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-5-nitro-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234426-78-9 CAPLUS

CN [1,1'-Biphenyl]-4-ol, 3-fluoro-2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234426-79-0 CAPLUS

CN Pyridine, 5-[3'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]-2-[(3-methyl-2-butenyl)oxy]- (9CI) (CA INDEX NAME)




RN 234426-80-3 CAPLUS

CN Pyridine, 5-(3'-fluoro-4'-methoxy-2,5-dimethyl[1,1'-biphenyl]-4-yl)-2-[(3-methyl-2-butenyl)oxy]- (9CI) (CA INDEX NAME)




RN 234426-81-4 CAPLUS

CN Pyridine, 5-[3'-fluoro-4'-(2-furanylmethoxy)-2,5-dimethyl[1,1'-biphenyl]-4-yl]-2-[(3-methyl-2-butenyl)oxy]- (9CI) (CA INDEX NAME)




RN 234426-82-5 CAPLUS

CN Pyridine, 5-[3'-fluoro-2,5-dimethyl-4'-(phenylmethoxy)[1,1'-biphenyl]-4-yl]-2-[(3-methyl-2-butenyl)oxy]- (9CI) (CA INDEX NAME)




RN 234426-85-8 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2-fluoro-2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[2-methyl-6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234426-86-9 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2-fluoro-2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[5-methyl-6-[(3-methyl-2-butenyloxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234426-87-0 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2-fluoro-2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[4-methyl-6-[(3-methyl-2-butenyloxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234426-88-1 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2-fluoro-2',5'-dimethyl-4'-[5-methyl-6-[(3-methyl-2-butenyloxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234426-89-2 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2-fluoro-2',5'-dimethyl-4'-[4-methyl-6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234426-90-5 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[2-methyl-6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234426-91-6 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[5-methyl-6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234426-92-7 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[4-methyl-6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234426-93-8 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2',5'-dimethyl-4'-[2-methyl-6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234426-94-9 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2',5'-dimethyl-4'-[5-methyl-6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234426-95-0 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2',5'-dimethyl-4'-[4-methyl-6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234426-96-1 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 4'-[6-(2-fluoroethoxy)-3-pyridinyl]-2',5'-dimethyl-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 234426-97-2 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2',5'-dimethyl-N-2-propynyloxy-4'-[6-(2-propynyloxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234426-98-3 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[6-(2-propynyloxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234426-99-4 CAPLUS


CN [1,1'-Biphenyl]-4-amine, 2-fluoro-2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[6-(4-methyl-3-pentenyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234427-00-0 CAPLUS


CN 2-Pyridinamine, 5-[3'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-

butenyl)oxy][1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 234427-01-1 CAPLUS

CN 2-Pyridinamine, 5-[2,5-dimethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 234427-02-2 CAPLUS

CN 2-Pyridinamine, 5-[3'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 234427-03-3 CAPLUS

CN 2-Pyridinamine, 5-[2,5-dimethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 234427-04-4 CAPLUS

CN 2-Pyridinamine, N-cyclohexyl-5-[2,5-dimethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 234427-05-5 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2-fluoro-4'-[6-(2-furanylmethoxy)-3-pyridinyl]-2',5'-dimethyl-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)



RN 234427-06-6 CAPLUS


CN [1,1'-Biphenyl]-4-amine, 4'-[6-(2-butynyl)-3-pyridinyl]-2-fluoro-2',5'-dimethyl-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)



RN 234427-07-7 CAPLUS


CN [1,1'-Biphenyl]-4-amine, 2-fluoro-2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[6-(2-furanylmethoxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)

[6-(1H-pyrrol-1-yl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234427-08-8 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2-fluoro-2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[6-(1-pyrrolidinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234427-09-9 CAPLUS

CN Pyridine, 3-[2,5-dimethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 234427-10-2 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 4'-(6-methoxy-3-pyridinyl)-2',5'-dimethyl-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 234427-11-3 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 4'-(6-methoxy-5-nitro-3-pyridinyl)-2',5'-dimethyl-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 234427-12-4 CAPLUS

CN Pyridine, 5-[3'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]-2-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 234427-13-5 CAPLUS

CN Pyridine, 5-[3'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 234427-14-6 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2',3',5',6'-tetramethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234427-15-7 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2',3',5',6'-tetramethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234427-16-8 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2',3',5',6'-tetramethyl-N-(1-methylethyl)-4'-[6-(2-propenyloxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234427-17-9 CAPLUS

CN Pyridine, 5-[3'-fluoro-2,3,5,6-tetramethyl-4'-[(3-methyl-2-butenyl)oxy] [1,1'-biphenyl]-4-yl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 234427-18-0 CAPLUS

CN 2-Pyridinamine, 5-[3'-fluoro-2,3,5,6-tetramethyl-4'-[(3-methyl-2-butenyl)oxy] [1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 234427-19-1 CAPLUS

CN 2-Pyridinamine, 5-[3'-fluoro-2,3,5,6-tetramethyl-4'-[(3-methyl-2-butenyl)oxy] [1,1'-biphenyl]-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 234427-20-4 CAPLUS

CN 2-Pyridinamine, N-(cyclohexylmethyl)-5-[3'-fluoro-2,3,5,6-tetramethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 234427-21-5 CAPLUS

CN 3-Pyridinemethanamine, N-[5-[3'-fluoro-2,3,5,6-tetramethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234427-22-6 CAPLUS

CN 2-Pyridinamine, 5-[3'-fluoro-2,3,5,6-tetramethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)




RN 234427-23-7 CAPLUS

CN 2-Pyridinamine, 5-[3'-fluoro-2,3,5,6-tetramethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 234427-24-8 CAPLUS

CN 2-Pyridinamine, 5-[3'-fluoro-2,3,5,6-tetramethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 234427-25-9 CAPLUS

CN 2-Pyridinamine, 5-[3'-fluoro-2,3,5,6-tetramethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]-N-(3-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 234427-26-0 CAPLUS

CN 2-Pyridinamine, 5-[3'-fluoro-2,3,5,6-tetramethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]-N-(2-furanylmethyl)- (9CI) (CA INDEX NAME)




RN 234427-27-1 CAPLUS

CN 2-Pyridinamine, 5-[3'-fluoro-2,3,5,6-tetramethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]-N-(3-furanylmethyl)- (9CI) (CA INDEX NAME)




RN 234427-28-2 CAPLUS

CN 2-Pyridinemethanamine, N-[5-[3'-fluoro-2,3,5,6-tetramethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234427-29-3 CAPLUS

CN 2-Pyridinamine, 5-[3'-fluoro-2,3,5,6-tetramethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 234427-30-6 CAPLUS

CN 2-Pyridinamine, 5-(4'-amino-2,3,5,6-tetramethyl[1,1'-biphenyl]-4-yl)-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 234427-31-7 CAPLUS

CN 2-Pyridinamine, N-(3-methyl-2-butenyl)-5-[2,3,5,6-tetramethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 234427-32-8 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2',3',5',6'-tetramethyl-4'-[6-[(3-methyl-2-butenyl)thio]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234427-33-9 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2',3',5',6'-tetramethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)thio]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234427-35-1 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2',3',5',6'-tetramethyl-4'-[2-methyl-6-[(3-methyl-2-butenyl)thio]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234427-36-2 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2',3',5',6'-tetramethyl-4'-[5-methyl-6-[(3-methyl-2-butenyl)thio]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234427-37-3 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2',3',5',6'-tetramethyl-4'-[4-methyl-6-[(3-methyl-2-butenyl)thio]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234427-39-5 CAPLUS

CN 2-Pyridinamine, 5-[3'-fluoro-2-methoxy-3,5,6-trimethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 234427-40-8 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2'-methoxy-3',5',6'-trimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234427-41-9 CAPLUS


CN [1,1'-Biphenyl]-4-amine, 2'-methoxy-3',5',6'-trimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234427-42-0 CAPLUS

CN Benzoic acid, 4-[[[2'-methoxy-3',5',6'-trimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl][1,1'-biphenyl]-4-yl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— OMe


RN 234427-43-1 CAPLUS

CN Benzoic acid, 4-[[[2'-methoxy-3',5',6'-trimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl][1,1'-biphenyl]-4-yl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 234427-44-2 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2'-methoxy-3',5',6'-trimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-N-[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 234427-45-3 CAPLUS

CN 2-Furanmethanamine, N-[[[2'-methoxy-3',5',6'-trimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 234427-46-4 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 3'-methoxy-2',5',6'-trimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234427-47-5 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 3'-methoxy-2',5',6'-trimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234427-48-6 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 3'-methoxy-2',5',6'-trimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 234427-49-7 CAPLUS

CN [1,1'-Biphenyl]-4-amine, N-cyclohexyl-3'-methoxy-2',5',6'-trimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234427-50-0 CAPLUS

CN 2-Furanmethanamine, N-[3'-methoxy-2',5',6'-trimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 234427-51-1 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 3'-methoxy-2',5',6'-trimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-N-2-propynyl- (9CI) (CA INDEX NAME)




RN 234427-52-2 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 3'-methoxy-2',5',6'-trimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 234427-53-3 CAPLUS

CN Pyridine, 5-[3-methoxy-2,5,6-trimethyl-4'-[(5-methyl-2-furanyl)methyl][1,1'-biphenyl]-4-yl]-2-[(3-methyl-2-butenyl)oxy]- (9CI)
(CA INDEX NAME)




RN 234427-54-4 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 3'-methoxy-2',5',6'-trimethyl-N-(2-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234427-55-5 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 3'-methoxy-2',5',6'-trimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-N-[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 234427-56-6 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 4'-[6-(2-butenyloxy)-3-pyridinyl]-3'-methoxy-2',5',6'-trimethyl-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 234427-57-7 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 3'-methoxy-2',5',6'-trimethyl-N-(3-methyl-2-butenyl)-4'-[6-(3-pentenyl-2-oxo)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234427-58-8 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 3'-methoxy-2',5',6'-trimethyl-N-(3-methyl-2-butenyl)-4'-[6-(2-pentenyl-2-oxo)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 234427-59-9 CAPLUS


CN [1,1'-Biphenyl]-4-amine, 4'-[6-(2-butynyl-2-oxo)-3-pyridinyl]-3'-methoxy-2',5',6'-trimethyl-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)



RN 234427-60-2 CAPLUS


CN [1,1'-Biphenyl]-4-amine, 4'-[6-(2-furanylmethoxy)-3-pyridinyl]-3'-methoxy-

2',5',6'-trimethyl-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 234427-61-3 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 4'-[6-(2-furanylmethoxy)-3-pyridinyl]-3'-methoxy-2',5',6'-trimethyl- (9CI) (CA INDEX NAME)




RN 234427-62-4 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 4'-[6-(2-fluoroethoxy)-3-pyridinyl]-3'-methoxy-2',5',6'-trimethyl-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 234427-63-5 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 3'-methoxy-2',5',6'-trimethyl-N-(3-methyl-2-butenyl)-4'-[6-(2,2,2-trifluoroethoxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234427-64-6 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 4'-[6-(2-furanylmethoxy)-3-pyridinyl]-3'-methoxy-2',5',6'-trimethyl-N-2-propynyl- (9CI) (CA INDEX NAME)




RN 234427-65-7 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 4'-[6-(2-butynyloxy)-3-pyridinyl]-3'-methoxy-2',5',6'-trimethyl-N-2-propynyl- (9CI) (CA INDEX NAME)




RN 234427-66-8 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 3'-methoxy-2',5',6'-trimethyl-N-(3-methyl-2-butenyl)-4'-[6-(methylthio)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234427-67-9 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 3'-methoxy-2',5',6'-trimethyl-N-(3-methyl-2-butenyl)-4'-[6-(methylsulfonyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234427-68-0 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2',5'-dimethoxy-3',6'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234427-69-1 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2',5'-dimethoxy-3',6'-dimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234427-71-5 CAPLUS

CN [1,1'-Biphenyl]-4-amine, N-cyclohexyl-2',5'-dimethoxy-3',6'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234427-72-6 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2',5'-dimethoxy-3',6'-dimethyl-N-(3-methyl-2-butenyl)-4'-[2-methyl-6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234427-73-7 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2',5'-dimethoxy-3',6'-dimethyl-N-(3-methyl-2-butenyl)-4'-[5-methyl-6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234427-74-8 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2',5'-dimethoxy-3',6'-dimethyl-N-(3-methyl-2-butenyl)-4'-[4-methyl-6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234427-75-9 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2',5'-dimethoxy-3',6'-dimethyl-N-(3-methyl-2-butenyl)-4'-[6-(methylthio)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234427-76-0 CAPLUS

CN 2-Pyridinamine, 5-[2,5-dimethoxy-3,6-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 234427-77-1 CAPLUS

CN 2-Pyridinamine, 5-[3'-fluoro-2,5-dimethoxy-3,6-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 234427-78-2 CAPLUS

CN 2-Pyridinamine, 5-[3'-fluoro-2,5-dimethoxy-3,6-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 234427-79-3 CAPLUS

CN 2-Pyridinamine, N-cyclohexyl-5-[3'-fluoro-2,5-dimethoxy-3,6-dimethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 234427-80-6 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2',3',6'-trimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234427-81-7 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2',3',6'-trimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 234427-82-8 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2'-methoxy-5'-methyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234427-83-9 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2'-methoxy-5'-methyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 234427-84-0 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2'-methoxy-5'-methyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 234427-85-1 CAPLUS

CN 1,4-Dioxaspiro[4.5]decan-8-amine, N-[2'-methoxy-5'-methyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 234427-86-2 CAPLUS

CN 2H-Pyran-4-amine, tetrahydro-N-[2'-methoxy-5'-methyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 234427-87-3 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 4'-[6-(2-furanylmethoxy)-3-pyridinyl]-2'-methoxy-5'-methyl-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 234427-88-4 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 4'-[6-(2-furanylmethoxy)-3-pyridinyl]-2'-methoxy-5'-methyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 234427-89-5 CAPLUS


CN 1,4-Dioxaspiro[4.5]decan-8-amine, N-[4'-[6-(2-furanylmethoxy)-3-pyridinyl]-2'-methoxy-5'-methyl[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 234427-90-8 CAPLUS



CN [1,1'-Biphenyl]-3-carboxylic acid, 6-methoxy-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino]-4-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-, methyl ester

(9CI) (CA INDEX NAME)




RN 234427-91-9 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 4-[6-(2-furanylmethoxy)-3-pyridinyl]-6-methoxy-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino]-, methyl ester (9CI)
(CA INDEX NAME)




RN 234427-92-0 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 3'-chloro-2',5',6'-trimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234427-93-1 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 3'-chloro-2',5',6'-trimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 234427-94-2 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 3'-methoxy-2,2',5'-trimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234427-95-3 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 3'-methoxy-2,2',5'-trimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 234427-96-4 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2-fluoro-3'-methoxy-2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234427-97-5 CAPLUS


CN [1,1'-Biphenyl]-4-amine, 2-fluoro-3'-methoxy-2',5'-dimethyl-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 234427-98-6 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 3,5,6-trimethyl-4'-[(3-methyl-2-butenyl)amino]-4-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 234427-99-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4-[6-(2-furanylmethoxy)-3-pyridinyl]-3,5,6-trimethyl-4'-[(3-methyl-2-butenyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 234428-00-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 3,5,6-trimethyl-4'-[(3-methyl-2-butenyl)amino]-4-[6-(2-propynyloxy)-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 234428-54-7 CAPLUS

CN 2(1H)-Pyridinone, 5-(4'-amino-2'-fluoro-2,5-dimethyl[1,1'-biphenyl]-4-yl)-
(9CI) (CA INDEX NAME)




RN 234428-55-8 CAPLUS

CN 2(1H)-Pyridinone, 5-(4'-amino-2'-chloro-2,5-dimethyl[1,1'-biphenyl]-4-yl)-
(9CI) (CA INDEX NAME)




RN 234428-56-9 CAPLUS

CN 2(1H)-Pyridinone, 5-[2'-chloro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 234428-57-0 CAPLUS

CN 2(1H)-Pyridinone, 5-[2'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 234428-58-1 CAPLUS

CN 2(1H)-Pyridinone, 5-[3'-fluoro-2,3,5,6-tetramethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




IT 234429-28-8

RL: RCT (Reactant); RACT (Reactant or reagent)
 (prepn. of tricyclic compds. as **immunosuppressants** and
 allergy inhibitors)

RN 234429-28-8 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2-fluoro-2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> s graft?  
L38      106726 GRAFT?  
  
=> s l35 and l38  
L39      2 L35 AND L38  
  
=> s l39 not l37  
L40      1 L39 NOT L37  
  
=> d l40 bib,ab,hitstr
```

L40 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:78224 CAPLUS
 DN 134:131433
 TI Preparation of tricyclic compounds as inhibitors of cell differentiation into Th2 cells
 IN Arimura, Akinori; Kawada, Kenji
 PA Shionogi & Co., Ltd., Japan
 SO PCT Int. Appl., 102 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001007032	A1	20010201	WO 2000-JP4725	20000714
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	BR 2000012697	A	20020409	BR 2000-12697	20000714
	EP 1206935	A1	20020522	EP 2000-946316	20000714
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	AU 763976	B2	20030807	AU 2000-60159	20000714
	ZA 2001009785	A	20021128	ZA 2001-9785	20011128
	NO 2001006401	A	20020123	NO 2001-6401	20011221
PRAI	JP 1999-209298	A	19990723		
	WO 2000-JP4725	W	20000714		

OS MARPAT 134:131433


AB The title compds. I [rings A, B and C are each an arom. carbon ring, a heterocycle, etc.; X represents a single bond, O, CH₂, NH, SO, etc.; Y represents hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, etc.; and V1 and V2 represent each a single bond, O, NH, OCH₂, etc.; when ring A, B, or C is (un)substituted 5-membered heterocyclic ring, W1, W2, W3 = bond] are prepd. Compds. of this invention at 40 mg/kg gave significant inhibition of Th0 cell differentiation into Th2 cells. Formulations are given.

IT **234426-58-5P 234427-63-5P 234427-78-2P**
234427-80-6P 234429-28-8P 321438-90-8P
321981-93-5P 322477-17-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of tricyclic compds. as inhibitors of cell differentiation into Th2 cells)


RN 234426-58-5 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234427-63-5 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 3'-methoxy-2',5',6'-trimethyl-N-(3-methyl-2-butenyl)-4'-[6-(2,2,2-trifluoroethoxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234427-78-2 CAPLUS

CN 2-Pyridinamine, 5-[3'-fluoro-2,5-dimethoxy-3,6-dimethyl-4'-[(3-methyl-2-butenyl)amino]-1,1'-biphenyl]-4-yl]-N-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 234427-80-6 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2',3',6'-trimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 234429-28-8 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2-fluoro-2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 321438-90-8 CAPLUS

CN 2(1H)-Pyridinone, 5-[2'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-, (1-methylethylidene)hydrazone (9CI) (CA INDEX NAME)




RN 321981-93-5 CAPLUS

CN 2-Propanone, O-[5-[2'-fluoro-2,5-dimethyl-4'-[(3-methyl-2-butenyl)amino][1,1'-biphenyl]-4-yl]-2-pyridinyl]oxime (9CI) (CA INDEX NAME)



RN 322477-17-8 CAPLUS

CN Pyridine, 5-[3'-fluoro-3-methoxy-2,5,6-trimethyl-4'-[(3-methyl-2-butenyl)oxy][1,1'-biphenyl]-4-yl]-2-[(3-methyl-2-butenyl)oxy]- (9CI) (CA INDEX NAME)




IT **321438-83-9P 321438-84-0P 321438-85-1P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of tricyclic compds. as inhibitors of cell differentiation into Th2 cells)


RN 321438-83-9 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2-fluoro-2',5'-dimethyl-4'-[6-(methylthio)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 321438-84-0 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[2-fluoro-2',5'-dimethyl-4'-[6-(methylthio)-3-pyridinyl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 321438-85-1 CAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[2-fluoro-2',5'-dimethyl-4'-[6-(methylsulfonyl)-3-pyridinyl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

=> s 134/thu

73 L34

554424 THU/RL

L41

18 L34/THU

(L34 (L) THU/RL)

=> s 141 not 137

L42

14 L41 NOT L37

=> s 142 not 140

L43

13 L42 NOT L40

=> d 143 1-13 bib,ab,hitstr

L43 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2003:300891 CAPLUS

DN 138:321134

TI Preparation of biphenylpyridine derivatives as dihydroorotate dehydrogenase inhibitors

IN Arimura, Akinori; Kishino, Junji; Tanimoto, Norihiko

PA Shionogi & Co., Ltd., Japan

SO PCT Int. Appl., 32 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003030905	A1	20030417	WO 2002-JP10030	20020927
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI JP 2001-305557 A 20011001

OS MARPAT 138:321134

AB The title compds. I [wherein R1 and R4 = independently alkyl or alkoxy; R2 and R3 = independently H or alkyl; R5 = H or halo; R6 = H or OH; X1 and X2 = independently O or NH] and prodrugs, pharmaceutically acceptable salts, and solvates thereof are prepd. as dihydroorotate dehydrogenase inhibitors. I are useful for the treatment of cancer, virus infection, chronic articular rheumatism, and transplant rejection (no data). For example, compd. II was prepd. in a multi-step synthesis. II showed IC50 of 17 ng/mL against human U-937 cell. Formulations contg. I as an active ingredient were also described.


IT 234429-28-8P 511538-15-1P 511538-16-2P
511538-17-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; prepn. of biphenylpyridine derivs. as dihydroorotate dehydrogenase inhibitors)


RN 234429-28-8 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2-fluoro-2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 511538-15-1 CAPLUS

CN [1,1'-Biphenyl]-3-ol, 2',5'-dimethoxy-3',6'-dimethyl-4-[(3-methyl-2-butenyl)oxy]-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 511538-16-2 CAPLUS

CN [1,1'-Biphenyl]-3-ol, 3'-methoxy-2',5',6'-trimethyl-4-[(3-methyl-2-butenyl)oxy]-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 511538-17-3 CAPLUS

CN [1,1'-Biphenyl]-3-ol, 3'-methoxy-2',5',6'-trimethyl-4'-[6-[(3-methyl-2-butenyl)amino]-3-pyridinyl]-4-[(3-methyl-2-butenyl)oxy]- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2002:632833 CAPLUS

DN 137:169427

TI 3-Pyridyloxymethyl heterocyclic ether compounds with nicotinic cholinergic activity, useful in controlling chemical synaptic transmission.

IN Lin, Nan-Horng; He, Yun; Holladay, Mark W.; Ryther, Keith; Li, Yihong; Bai, Hao

PA Abbott Laboratories, USA

SO U.S., 66 pp., Cont.-in-part of U.S. 6,127,386.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6437138	B1	20020820	US 2000-472399	20000301
	US 5629325	A	19970513	US 1996-660044	19960606
	US 6127386	A	20001003	US 1997-844540	19970418
PRAI	US 1996-660044	A2	19960606		
	US 1997-844540	A2	19970418		

OS MARPAT 137:169427

AB Novel 3-pyridyloxymethyl heterocyclic ether compds. I and their pharmaceutically acceptable salts or prodrugs are disclosed [wherein: n = 1-3; R1 = H, allyl, alkyl; R2 = H, alkyl, F, Cl, ethenyl, Ph; L = bond, alkylene, C.tplbond.C-alkyl, (CH:CH)1-2-alkyl, CH:CHCO-alkyl, CO-alkyl, CH2-M-CO--alkyl; M = CH2 or NH; R3 = H, alkyl, alkenyl, haloalkyl, hydroxyalkyl, alkoxy, (di)(alkyl)amino, (un)substituted aryl or heteroaryl; or LR3 = OCH2R4; R4 = CH2OMe, dialkylamino, (un)substituted aryl or heteroaryl; with provisos]. The compds. are selective and potent ligands at neuronal nicotinic cholinergic channel receptors. Over 200 examples are given. For example, vinylation of 3-(1-BOC-2-(S)-pyrrolidinylmethoxy)-5-bromo-6-chloropyridine (prepn. given) with vinyltributyltin in the presence of Pd(PPh3)4 in PhMe (85%), followed by deprotection and salification with HCl in dioxane (86%), gave title substance II.bul.HCl. This substance bound to neuronal nicotinic receptors in vitro with a Ki of 0.035 nM. Compds. I also activated or inhibited neuronal nicotinic receptor channels in IMR-32 cells in vitro.

IT **191162-20-6P**, 5-(4'-Methyl-4-biphenyl)-3-(2-(S)-pyrrolidinylmethoxy)pyridine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; prepn. of pyridyloxymethyl heterocyclic ethers as nicotinic cholinergic receptor ligands)

RN 191162-20-6 CAPLUS

CN Pyridine, 3-(4'-methyl[1,1'-biphenyl]-4-yl)-5-[(2S)-2-pyrrolidinylmethoxy]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

ENS binary




RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:873190 CAPLUS
 DN 136:642
 TI Tricyclic compounds as apo-AI expression stimulants for treatment of cardiovascular diseases
 IN Ishizuka, Natsuki; Sakai, Katsunori; Hayashi, Kunio
 PA Shionogi and Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 22 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2001335476	A2	20011204	JP 2000-157866	20000529
	WO 2003024441	A1	20030327	WO 2001-JP7979	20010914

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI JP 2000-157866 A 20000529
 OS MARPAT 136:642
 AB Tricyclic compds. (I; X1, X2 = aryl, hetero aryl, H, halogen, etc.; A = condensed ring, arom. hetero ring of 6 members which including N atom (1-3); R1-R4 = H, halogen, low alkyl, low alkoxy, etc.) and their pharmaceutically acceptable salts are claimed as apo-AI expression stimulants for treatment of cardiovascular diseases, including hyperlipidemia and atherosclerosis. Formulation examples of I tablets, capsules, and granules were given.
 IT 101868-82-0P 377047-59-1P 377047-60-4P 377047-61-5P
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
 (tricyclic compds. as apo-AI expression stimulants for treatment of cardiovascular diseases)
 RN 101868-82-0 CAPLUS
 CN Acetamide, N-[4'-(2-pyridinyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 377047-59-1 CAPLUS
 CN Pyridine, 2-(4'-methoxy[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)




RN 377047-60-4 CAPLUS

CN [1,1'-Biphenyl]-4-ol, 4'-(2-pyridinyl)-, acetate (ester) (9CI) (CA INDEX NAME)



RN 377047-61-5 CAPLUS

CN Pyridine, 2-(4'-methyl[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)



L43 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2001:762806 CAPLUS

DN 135:322727

TI Oil-in-water microemulsions containing tricyclic compounds or pre concentrates thereof

IN Kawakami, Kohsaku; Yoshikawa, Takayoshi

PA Shionogi + Co., Ltd., Japan

SO PCT Int. Appl., 46 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001076582	A1	20011018	WO 2001-JP2617	20010329
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRAI JP 2000-102933 A 20000405

OS MARPAT 135:322727


AB Disclosed are microemulsions which contain a tricyclic compd., pharmaceutically acceptable salts thereof, and solvates of both, a monoester of glycerol with a fatty acid and/or a monoester of propylene glycol with a fatty acid, and a surfactant; and preconcs. of the microemulsions. A microemulsion preconc. for oral administration contained 2-fluoro-2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]-[1,1'-biphenyl]-4-amine 50, Homotex PT 400, Sefsol-228 400, and Tween-80 359 mg.

IT 234429-28-8

RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses) (microemulsions contg. tricyclic compds. and solubilizers and surfactants)

RN 234429-28-8 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2-fluoro-2',5'-dimethyl-N-(3-methyl-2-butenyl)-4'-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:747580 CAPLUS
 DN 135:278052
 TI Oily compositions containing highly fat-soluble drugs
 IN Nishihara, Yoshitaka; Kinoshita, Haruki; Yoshikawa, Takayoshi
 PA Shionogi + Co., Ltd., Japan
 SO PCT Int. Appl., 50 pp.
 CODEN: PIXXD2

DT Patent
 LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001074331	A1	20011011	WO 2001-JP2621	20010329
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 2001044614	A5	20011015	AU 2001-44614	20010329
	EP 1273287	A1	20030108	EP 2001-917589	20010329
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	US 2003149061	A1	20030807	US 2002-240602	20021003
PRAI	JP 2000-102272	A	20000404		
	WO 2001-JP2621	W	20010329		

OS MARPAT 135:278052


AB Disclosed are oily compns. which contain as the principal agent highly fat-sol. drugs, pharmaceutically acceptable salts and solvates thereof and further contain (1) a triester of glycerol with a medium-chain fatty acid and/or an ester of propylene glycol with a medium-chain fatty acid, (2) a triester of glycerol with a long-chain fatty acid, and (3) a surfactant. An emulsion contained 3''-fluoro-2',3',5',6'-tetramethyl-N-(3-methyl-2-butenyl)-4''-[(3-methyl-2-butenyl)oxy]-[1,1':4',1''-terphenyl]-4-amine 10 %, Miglyol-812 60 %, avocado oil 10 %, and sorbitan monopalmitate 20 %.

IT 234429-28-8

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (oily compns. contg. highly fat-sol. drugs)

RN 234429-28-8 CAPLUS

CN [1,1'-Biphenyl]-4-amine, 2-fluoro-2',5'-dimethyl-N-(3-methyl-2-butenyl)-4''-[6-[(3-methyl-2-butenyl)oxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD

L43 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2000:841966 CAPLUS
 DN 134:13350
 TI Nitric oxide synthase (NOS) inhibitor combinations with other agents for
 treatment of disorders treatable by altering circadian rhythm
 IN Saltarelli, Mario David; Lowe, John Adams, III
 PA Pfizer Products Inc., USA
 SO PCT Int. Appl., 113 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000071107	A2	20001130	WO 2000-IB295	20000316
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	EP 1178784	A1	20020213	EP 2000-907891	20000316
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	BR 2000010820	A	20020305	BR 2000-10820	20000316
	EE 200100611	A	20030217	EE 2001-611	20000316
	JP 2003523941	T2	20030812	JP 2000-619414	20000316
	NO 2001005651	A	20020118	NO 2001-5651	20011120
	BG 106208	A	20020930	BG 2001-106208	20011211
PRAI	US 1999-135520P	P	19990521		
	WO 2000-IB295	W	20000316		

AB New pharmaceutical uses are provided for compds. that exhibit activity as NOS inhibitors. Specifically, the invention provides the use of NOS inhibitors, particularly selective neuronal NOS (nNOS) inhibitors, alone or in combination with another active agent, in particular, either a selective serotonin reuptake inhibitor (SSRI) or an NK-1 receptor antagonist, for the treatment of disorders or conditions the treatment which can be effected or facilitated by altering circadian rhythms. Examples of such disorders and conditions are blindness, obesity, seasonal affective disorder, bipolar disorder, jet lag, circadian sleep rhythms disorder, sleep deprivation, parasomnias, REM sleep disorders, hypersomnia, sleep-wake cycle disorders, narcolepsy and sleep disorders assocd. with shift work or irregular work schedules; nocturnal enuresis, and restless-legs syndrome.


IT 208837-09-6 310433-38-6 310433-39-7
 310433-40-0

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(nitric oxide synthase inhibitor combinations with other agents for treatment of disorders treatable by altering circadian rhythm)


RN 208837-09-6 CAPLUS

CN 2-Pyridinamine, 6-[4'-[(3,4-dihydro-5,6-dimethoxy-2(1H)-isoquinolinyl)methyl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 310433-38-6 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-[2-[4'-(6-amino-2-pyridinyl)[1,1'-biphenyl]-4-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 310433-39-7 CAPLUS

CN 2-Pyridinamine, 6-[4'-[[4-(2-phenylethyl)-1-piperazinyl]methyl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 310433-40-0 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-[[4'-(6-amino-2-pyridinyl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



L43 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2000:699189 CAPLUS

DN 133:281694

TI 3-Pyridyloxymethyl heterocyclic ether compounds with nicotinic cholinergic activity, useful in controlling chemical synaptic transmission.

IN Lin, Nan-horng; He, Yun; Holladay, Mark W.; Ryther, Keith B.; Li, Yihong; Bai, Hao

PA Abbott Laboratories, USA

SO U.S., 74 pp., Cont.-in-part of U.S. Ser. No. 660,044.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6127386	A	20001003	US 1997-844540	19970418
	US 5629325	A	19970513	US 1996-660044	19960606
	JP 2002515038	T2	20020521	JP 1998-500686	19970604
	US 6437138	B1	20020820	US 2000-472399	20000301
PRAI	US 1996-660044	A2	19960606		
	US 1997-844540	A	19970418		
	WO 1997-US9167	W	19970604		

OS MARPAT 133:281694

AB Novel 3-pyridyloxymethyl heterocyclic ether compds. I and their pharmaceutically acceptable salts or prodrugs are disclosed [wherein: n = 1-3; R1 = H, allyl, C1-6 alkyl; R2 = H, C1-3 alkyl, F, Cl, ethenyl, Ph; L = bond, C1-6 alkylene, C.tplbond.C-(C0-6-alkyl), (CH:CH)1-2-(C0-6-alkyl), CH:CHCO-(C0-6-alkyl), CO-(C0-6-alkyl), CH2-M-CO-(C0-6-alkyl); M = CH2 or NH; R3 = H, C1-8 alkyl, C2-6 alkenyl, C1-6 haloalkyl, hydroxyalkyl, alkoxy, (di)(alkyl)amino, (un)substituted aryl or heteroaryl; or LR3 = OCH2R4; R4 = CH2OMe, dialkylamino, (un)substituted aryl or heteroaryl; with provisos]. Claims include compds. I, prepn. of I via certain halopyridine intermediates, pharmaceutical compns. contg. I, and use of I to control synaptic transmission. The compds. are selective and potent ligands at neuronal nicotinic cholinergic channel receptors. Over 200 examples are given, most including phys. data for I. For example, vinylation of 3-(1-BOC-2-(S)-pyrrolidinylmethoxy)-5-bromo-6-chloropyridine (prepn. given) with vinyltributyltin in the presence of Pd(PPh3)4 in PhMe (85%), followed by deprotection and salification with HCl in dioxane (86%), gave title substance II.HCl. This substance bound to neuronal nicotinic receptors in vitro with a Ki of 0.035 nM. Compds. I also activated or inhibited neuronal nicotinic receptor channels in IMR-32 cells in vitro.

IT **191162-20-6P**, 5-(4'-Methyl-4-biphenyl)-3-(2-(S)-pyrrolidinylmethoxy)pyridine


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; prepn. of pyridyloxymethyl heterocyclic ethers as nicotinic cholinergic receptor ligands)

RN 191162-20-6 CAPLUS

CN Pyridine, 3-(4'-methyl[1,1'-biphenyl]-4-yl)-5-[(2S)-2-pyrrolidinylmethoxy]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1998:394325 CAPLUS
 DN 129:67702
 TI Preparation of 6-phenylpyridyl-2-amines as NOS inhibitors
 IN Lowe, John Adams III
 PA Pfizer Inc., USA; Lowe, John Adams III
 SO PCT Int. Appl., 61 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9824766	A1	19980611	WO 1997-IB1446	19971117
	W:				
	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,				
	DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC,				
	LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,				
	RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN,				
	YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,				
	GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,				
	GN, ML, MR, NE, SN, TD, TG				
	AU 9747917	A1	19980629	AU 1997-47917	19971117
	EP 946512	A1	19991006	EP 1997-910587	19971117
	EP 946512	B1	20031008		
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,				
	SI, LT, LV, FI, RO				
	CN 1239952	A	19991229	CN 1997-180350	19971117
	CN 1117077	B	20030806		
	JP 2000505814	T2	20000516	JP 1998-525397	19971117
	NZ 335733	A	20010126	NZ 1997-335733	19971117
	AT 251612	E	20031015	AT 1997-910587	19971117
	TW 491840	B	20020621	TW 1997-86117501	19971122
	ZA 9710906	A	19990609	ZA 1997-10906	19971204
	AP 848	A	20000609	AP 1997-1156	19971204
	W:				
	BW, GM, KE, UG, ZM, ZW				
	US 6235750	B1	20010522	US 1999-325480	19990603
	NO 9902725	A	19990604	NO 1999-2725	19990604
	KR 2000057413	A	20000915	KR 1999-704981	19990604
	BG 103540	A	20001229	BG 1999-103540	19990630
	US 2002032191	A1	20020314	US 2001-802086	20010308
	AU 766080	B2	20031009	AU 2001-72050	20010913
	AU 2001072050	A5	20011115		
	US 2002103227	A1	20020801	US 2001-965564	20010927
PRAI	US 1996-32793P	P	19961206		
	AU 1997-47917	A3	19971117		
	WO 1997-IB1446	W	19971117		
	US 1999-325480	A1	19990603		
	US 2001-802086	B3	20010308		
OS	MARPAT 129:67702				
AB	The title compds. [I; G = II, III (n = 0, 1; Y = NR3R4, C1-6 alkyl, (un)substituted aralkyl; X = N when Y = (un)substituted C1-6 alkyl, aralkyl, and X = CH when Y = NR3R4; q = 0-2; m = 0-2; R3, R4 = C1-6 alkyl, tetrahydronaphthalene and aralkyl; NR3R4 = piperazino, pyrrolidino, etc.)] and their salts, which exhibit activity as nitric oxide synthase (NOS) inhibitors and as such useful in the treatment and prevention of central nervous system and other disorders, were prep'd. Thus, e.g., the detailed 7-step synthesis of the title compd. IV is described. Of 100 compds. I				


that were tested, all exhibited an IC50 of < 10 .mu.M for inhibition of either inducible or neuronal NOS.

IT 208836-72-0P 208836-73-1P 208836-75-3P
208837-09-6P 208837-37-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 6-phenylpyridyl-2-amines as NOS inhibitors)


RN 208836-72-0 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, N-[2-[4'-(6-amino-2-pyridinyl)[1,1'-biphenyl]-4-yl]ethyl]- (9CI) (CA INDEX NAME)



RN 208836-73-1 CAPLUS

CN 2-Pyridinamine, 6-[4'-[[4-(2-phenylethyl)-1-piperazinyl]methyl][1,1'-biphenyl]-4-yl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 208836-75-3 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, N-[[4'-(6-amino-2-pyridinyl)[1,1'-biphenyl]-4-yl]methyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 208836-74-2


CMF C23 H24 N4



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 208837-09-6 CAPLUS

CN 2-Pyridinamine, 6-[4'-[(3,4-dihydro-5,6-dimethoxy-2(1H)-isoquinolinyl)methyl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)



RN 208837-37-0 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, N-[2-[4'-(6-amino-2-pyridinyl)[1,1'-biphenyl]-4-yl]ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L43 ANSWER 10 OF 13 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1997:533540 CAPLUS
 DN 127:205892
 TI Semisynthesis of cyclic peptide antifungal and antiparasitic agents
 IN Henle, Stacy K.; Turner, William W., Jr.
 PA Eli Lilly and Co., USA
 SO PCT Int. Appl., 68 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9727864	A1	19970807	WO 1997-US1607	19970129
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	CA 2244238	AA	19970807	CA 1997-2244238	19970129
	AU 9718517	A1	19970822	AU 1997-18517	19970129
	EP 881907	A1	19981209	EP 1997-904148	19970129
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI			
	JP 2001503015	T2	20010306	JP 1997-527861	19970129
PRAI	US 1996-10946P	P	19960201		
	GB 1996-3151	A	19960215		
	WO 1997-US1607	W	19970129		
OS	MARPAT 127:205892				
AB	Cyclic peptide compds. I [R1 = H, Me, CH2CH2NH2, CH2CONH2; R2, R3 = independently H, Me; R4 = H, OH, NHR, OR; R = C1-6 alkyl, CH2Ph, (CH2)2SiMe3, etc.; R5, R6, R7, R8, R9 = independently H, OH; R10 = H, OPO3H2, OP(O)(OH)R12, OP(O)(OH)OR12; R12 = C1-6 alkyl, Ph, CH2Ph 4-halophenyl, 4-nitrobenzyl, etc.; R11 = A-X-B-Y-C-R13; A, B, C = independently Ph, furanyl, thiophenyl, 6 membered N-contg.-heterocyclyl; X, Y = independently bond, C.tplbond.C; R13 = C1-12 alkyl, C1-12 alkoxy, O-(CH2)m-[O-(CH2)n]p-O-(C1-12 alkyl); m, n = 2-4; p = 0, 1] or a pharmaceutically acceptable salt thereof, were prepd. as antifungal and antiparasitic agents. In particular, echinocandin cyclic deriv. compds. and pharmaceutical compns. thereof, are disclosed. For example, acylation of antibiotic A-30912A nucleus (II, R14 = H) with the N1-hydroxybenzotriazole ester of HO-Q1 (prepn. given) in DMF gave II (R14 = Q1). Prepd. agents I inhibited C albicans in vitro in mice with MIC values of 0.78 to .002 .mu.g/mL and in vivo in mice with ED50 values of >2.5 to 0.31 mg/kg.				
IT	194482-23-0P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use) ; BIOL (Biological study); PREP (Preparation); USES (Uses) (semisynthesis of cyclic peptide antifungal and antiparasitic agents)				
RN	194482-23-0 CAPLUS				
CN	Cilofungin, 1-[(4R,5R)-4,5-dihydroxy-N2-[[6-[4'-(pentyloxy)[1,1'-biphenyl]-4-yl]-3-pyridinyl]carbonyl]-L-ornithine]- (9CI) (CA INDEX NAME)				

PAGE 1-A



PAGE 2-A



L43 ANSWER 11 OF 13 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1997:341980 CAPLUS

DN 127:50541

TI 3-Pyridyloxymethyl heterocyclic ether compounds useful as nicotinic cholinergic ligands in controlling chemical synaptic transmission

IN Lin, Nan-horng; He, Yun; Holladay, Mark W.; Ryther, Keith; Li, Yihong

PA Abbott Laboratories, USA

SO U.S., 44 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5629325	A	19970513	US 1996-660044	19960606
	US 6127386	A	20001003	US 1997-844540	19970418
	WO 9746554	A1	19971211	WO 1997-US9167	19970604
	W: CA, JP, MX				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP	934308	A1	19990811	EP 1997-927830	19970604
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	JP 2002515038	T2	20020521	JP 1998-500686	19970604
	US 6437138	B1	20020820	US 2000-472399	20000301
PRAI	US 1996-660044	A2	19960606		
	US 1997-844540	A	19970418		
	WO 1997-US9167	W	19970604		

OS MARPAT 127:50541

AB Novel 3-pyridyloxymethyl heterocyclic ether compds. I [n = 1-3; R1 = H, allyl, C1-6 alkyl; R2 = H, F, Cl, vinyl, Ph; L = bond, C1-6 alkylene, C.tplbond.C, (CH:CH)p, CO, CH2MCO; p = 1, 2; M = CH2, NH; R3 = H, C1-6 alkyl, alkoxy, (di)(alkyl)amino, Ph, naphthyl, certain heterocyclyl, etc.; with provisos] and their pharmaceutically acceptable salts and prodrugs are selective and potent ligands at neuronal nicotinic cholinergic channel receptors, and are effective in controlling synaptic transmission. For instance, (S)-1-methyl-2-pyrrolidinemethanol was etherified with 3,5-dibromopyridine using NaH in DMF, and the product monobromide was coupled with 1-hexyne using Pd(PPh3)2Cl2 and CuI, to give title compd. II. In a test for inhibition of neuronal nicotinic cholinergic channels in IMR-32 cells in vitro, II.2HCl gave 55% inhibition at 1 .mu.M.


IT 191162-20-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyridyloxymethyl heterocyclic ethers as nicotinic cholinergic agents)

RN 191162-20-6 CAPLUS

CN Pyridine, 3-(4'-methyl[1,1'-biphenyl]-4-yl)-5-[(2S)-2-pyrrolidinylmethoxy]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L43 ANSWER 12 OF 13 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1996:462227 CAPLUS

DN 125:115150

TI Cyclic hexapeptides having antibiotic activity

IN Ohki, Hidenori; Tomishima, Masaki; Yamada, Akira; Takasugi, Hisashi

PA Fujisawa Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 273 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9611210	A1	19960418	WO 1995-JP1983	19950929
	W: AU, CA, CN, FI, HU, JP, KR, MX, NO, RU, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2202058	AA	19960418	CA 1995-2202058	19950929
	AU 9535780	A1	19960502	AU 1995-35780	19950929
	AU 696949	B2	19980924		
	EP 788511	A1	19970813	EP 1995-932935	19950929
	EP 788511	B1	20021211		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CN 1168675	A	19971224	CN 1995-196643	19950929
	JP 10507174	T2	19980714	JP 1995-512472	19950929
	JP 2897427	B2	19990531		
	HU 77736	A2	19980728	HU 1998-338	19950929
	JP 10324695	A2	19981208	JP 1998-136756	19950929
	RU 2165423	C2	20010420	RU 1997-107338	19950929
	AT 229541	E	20021215	AT 1995-932935	19950929
	ES 2187575	T3	20030616	ES 1995-932935	19950929
	IL 115484	A1	20000716	IL 1995-115484	19951002
	ZA 9508458	A	19960507	ZA 1995-8458	19951006
	BR 9504791	A	19961022	BR 1995-4791	19951006
	FI 9701397	A	19970527	FI 1997-1397	19970404
	NO 9701544	A	19970604	NO 1997-1544	19970404
	US 6107458	A	20000822	US 1997-809723	19970521
	US 6265536	B1	20010724	US 1999-248267	19990211
PRAI	GB 1994-20425	A	19941007		
	GB 1995-8745	A	19950428		
	JP 1996-512472	A3	19950929		
	WO 1995-JP1983	W	19950929		
	US 1997-809723	A3	19970521		

OS MARPAT 125:115150

AB The invention relates to new cyclic polypeptide derivs. I [R1 = variety of substituted acyl groups] and their pharmaceutically acceptable salts. The compds. have antimicrobial activities (esp., antifungal activities) and inhibitory activity on .beta.-1,3-glucan synthase (no data), and are useful for prophylactic and/or therapeutic treatment of infectious diseases including Pneumocystis carinii infection (e.g., P. carinii pneumonia). Examples include 124 compds. I, plus 346 precursor prepsns. For instance, reaction of the precursor I.Na [R1 = H] with 1-[6-[(octyloxy)methyl]picolinoyl]benzotriazole 3-oxide in DMF in the presence of DMAP gave title compd. I [R1 = Q1]. In a test against Candida albicans FP-633 in vitro, I [R1 = Q2] had MIC of 0.2 .mu.g/mL.

IT 179165-96-9P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic


use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of cyclic hexapeptides active against fungi and *Pneumocystis carinii*)

RN 179165-96-9 CAPLUS

CN Proline, N2-[[6-(4'-butoxy[1,1'-biphenyl]-4-yl)-3-pyridinyl]carbonyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6.fwdarw.1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A





● Na

L43 ANSWER 13 OF 13 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1995:849163 CAPLUS

DN 123:256498

TI Preparation of (benzoheteroaryl)methylguanidine calcium- and/or sodium-channel blockers

IN Lucchetti, Jean; Rinaldi, Murielle; Pialot, Françoise; Merschaert, Alain

PA Sanofi, Fr.

SO PCT Int. Appl., 132 pp.

CODEN: PIXXD2

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9504052	A1	19950209	WO 1994-FR962	19940728
	W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LV, MD, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, US, UZ, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	FR 2708609	A1	19950210	FR 1993-9362	19930729
	FR 2708609	B1	19951020		
	AU 9473870	A1	19950228	AU 1994-73870	19940728
	ZA 9405597	A	19960129	ZA 1994-5597	19940728
	EP 711290	A1	19960515	EP 1994-923764	19940728
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 09500895	T2	19970128	JP 1994-505627	19940728
	HU 75118	A2	19970428	HU 1996-179	19940728
PRAI	FR 1993-9362		19930729		
	WO 1994-FR962		19940728		

OS MARPAT 123:256498

AB 0The title compds. [I; R1-R3 = H, halogen, alkyl, alkoxy, Ph, PhCH₂; R4, R5 = H, C6-12 alkyl, benzhydryl, (un)substituted aralkyl, etc; X = O, S, (un)substituted NH; Y = (un)substituted heterocyclic or 2,3-dihydro heterocyclic residue; R1-R3 = C4-6 cyclic hydrocarbon including the C atoms at positions 5 and 6; * = asym. C] [e.g., 1-[2-methoxy-5-[4-(N-hexamethyleneimino)butyl]phenyl]-1-(2-benzofuryl)methylguanidine benzoate; m.p. 135.degree.], useful as sodium- and/or calcium-channel blockers (no data) for the treatment of a variety of claimed diseases (no data), are prepd.

IT 168822-70-6P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL

(Biological study); PREP (Preparation); USES (Uses)

(prepn. of (benzoheteroaryl)methylguanidine calcium- and sodium-channel blockers)


RN 168822-70-6 CAPLUS

CN Carbonic acid, compd. with [2-benzofuranyl[4-methoxy-4'-(2-pyridinyl)[1,1'-biphenyl]-3-yl]methyl]guanidine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 168822-69-3


CMF C28 H24 N4 O2



CM 2

CRN 463-79-6

CMF C H2 O3



09/980,475

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

97.19

408.90

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-12.37

-12.37

STN INTERNATIONAL LOGOFF AT 19:10:40 ON 04 DEC 2003